CA2322699A1 - Compositions and methods for enhanced antigen delivery to antigen presenting cells in vivo - Google Patents
Compositions and methods for enhanced antigen delivery to antigen presenting cells in vivo Download PDFInfo
- Publication number
- CA2322699A1 CA2322699A1 CA002322699A CA2322699A CA2322699A1 CA 2322699 A1 CA2322699 A1 CA 2322699A1 CA 002322699 A CA002322699 A CA 002322699A CA 2322699 A CA2322699 A CA 2322699A CA 2322699 A1 CA2322699 A1 CA 2322699A1
- Authority
- CA
- Canada
- Prior art keywords
- antigen
- cells
- factor
- cell
- apc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000612 antigen-presenting cell Anatomy 0.000 title claims abstract description 133
- 238000000034 method Methods 0.000 title claims abstract description 123
- 239000000427 antigen Substances 0.000 title claims abstract description 102
- 108091007433 antigens Proteins 0.000 title claims abstract description 102
- 102000036639 antigens Human genes 0.000 title claims abstract description 102
- 238000001727 in vivo Methods 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title abstract description 26
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 61
- 108700019146 Transgenes Proteins 0.000 claims abstract description 21
- 230000002708 enhancing effect Effects 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 172
- 108090000623 proteins and genes Proteins 0.000 claims description 113
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 56
- 230000035755 proliferation Effects 0.000 claims description 55
- 230000007115 recruitment Effects 0.000 claims description 53
- 102000004169 proteins and genes Human genes 0.000 claims description 43
- 102000040430 polynucleotide Human genes 0.000 claims description 37
- 108091033319 polynucleotide Proteins 0.000 claims description 37
- 239000002157 polynucleotide Substances 0.000 claims description 37
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 25
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 102000004127 Cytokines Human genes 0.000 claims description 14
- 108090000695 Cytokines Proteins 0.000 claims description 14
- 102000004388 Interleukin-4 Human genes 0.000 claims description 13
- 108090000978 Interleukin-4 Proteins 0.000 claims description 13
- 238000001476 gene delivery Methods 0.000 claims description 11
- 239000003102 growth factor Substances 0.000 claims description 10
- 229940028885 interleukin-4 Drugs 0.000 claims description 10
- 239000003226 mitogen Substances 0.000 claims description 9
- 108020004635 Complementary DNA Proteins 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 230000037452 priming Effects 0.000 claims description 8
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims description 7
- 101800001271 Surface protein Proteins 0.000 claims description 7
- 108020004999 messenger RNA Proteins 0.000 claims description 7
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims description 6
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 6
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 6
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 claims description 6
- 230000003399 chemotactic effect Effects 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 108010083700 Chemokine CCL20 Proteins 0.000 claims description 5
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 5
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 5
- 230000000770 proinflammatory effect Effects 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 102000003425 Tyrosinase Human genes 0.000 claims description 4
- 108060008724 Tyrosinase Proteins 0.000 claims description 4
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims description 2
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 108010008707 Mucin-1 Proteins 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 claims description 2
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 4
- 102100036850 C-C motif chemokine 23 Human genes 0.000 claims 2
- 102000006432 Chemokine CCL20 Human genes 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 1
- 238000010361 transduction Methods 0.000 abstract description 9
- 230000026683 transduction Effects 0.000 abstract description 9
- 230000003190 augmentative effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 description 78
- 210000004443 dendritic cell Anatomy 0.000 description 46
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 39
- 241000700605 Viruses Species 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 22
- 230000001177 retroviral effect Effects 0.000 description 21
- 230000001225 therapeutic effect Effects 0.000 description 21
- 210000001744 T-lymphocyte Anatomy 0.000 description 20
- 201000011510 cancer Diseases 0.000 description 19
- 238000001415 gene therapy Methods 0.000 description 19
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 16
- 230000003612 virological effect Effects 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 210000001616 monocyte Anatomy 0.000 description 14
- 238000012546 transfer Methods 0.000 description 14
- 238000004806 packaging method and process Methods 0.000 description 13
- 239000011324 bead Substances 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 241000701161 unidentified adenovirus Species 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 239000013603 viral vector Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- -1 S-fluorouracil Chemical compound 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 239000012642 immune effector Substances 0.000 description 8
- 229940121354 immunomodulator Drugs 0.000 description 8
- 210000005259 peripheral blood Anatomy 0.000 description 8
- 239000011886 peripheral blood Substances 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 108700028369 Alleles Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 241000702421 Dependoparvovirus Species 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 210000004754 hybrid cell Anatomy 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 108090000994 Catalytic RNA Proteins 0.000 description 5
- 102000053642 Catalytic RNA Human genes 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 108010057464 Prolactin Proteins 0.000 description 5
- 102000003946 Prolactin Human genes 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229940097325 prolactin Drugs 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 108091092562 ribozyme Proteins 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 4
- 102000006354 HLA-DR Antigens Human genes 0.000 description 4
- 108010058597 HLA-DR Antigens Proteins 0.000 description 4
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 4
- 102100034353 Integrase Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108010038807 Oligopeptides Proteins 0.000 description 4
- 102000015636 Oligopeptides Human genes 0.000 description 4
- 101150006914 TRP1 gene Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000003710 calcium ionophore Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 108010078428 env Gene Products Proteins 0.000 description 4
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000012239 gene modification Methods 0.000 description 4
- 230000005017 genetic modification Effects 0.000 description 4
- 235000013617 genetically modified food Nutrition 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 210000001821 langerhans cell Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102100034349 Integrase Human genes 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000006041 cell recruitment Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 102000046157 human CSF2 Human genes 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 229910052754 neon Inorganic materials 0.000 description 3
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
- HPZMWTNATZPBIH-UHFFFAOYSA-N 1-methyladenine Chemical compound CN1C=NC2=NC=NC2=C1N HPZMWTNATZPBIH-UHFFFAOYSA-N 0.000 description 2
- RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100036845 C-C motif chemokine 22 Human genes 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 108010083701 Chemokine CCL22 Proteins 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 206010064912 Malignant transformation Diseases 0.000 description 2
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 2
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
- HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 101000884281 Rattus norvegicus Signal transducer CD24 Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 241000713880 Spleen focus-forming virus Species 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000027296 dendritic cell chemotaxis Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000036212 malign transformation Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 238000010422 painting Methods 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- SATCOUWSAZBIJO-UHFFFAOYSA-N 1-methyladenine Natural products N=C1N(C)C=NC2=C1NC=N2 SATCOUWSAZBIJO-UHFFFAOYSA-N 0.000 description 1
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
- SVBOROZXXYRWJL-UHFFFAOYSA-N 2-[(4-oxo-2-sulfanylidene-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=S)NC1=O SVBOROZXXYRWJL-UHFFFAOYSA-N 0.000 description 1
- LLWPKTDSDUQBFY-UHFFFAOYSA-N 2-[6-(aminomethyl)-2,4-dioxo-1H-pyrimidin-5-yl]acetic acid Chemical compound C(=O)(O)CC=1C(NC(NC=1CN)=O)=O LLWPKTDSDUQBFY-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
- KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
- GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
- HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
- 108010087905 Adenovirus E1B Proteins Proteins 0.000 description 1
- 102100030343 Antigen peptide transporter 2 Human genes 0.000 description 1
- 108700032225 Antioxidant Response Elements Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- DRCNRVYVCHHIJP-AQBORDMYSA-N Arg-Lys-Glu-Val-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DRCNRVYVCHHIJP-AQBORDMYSA-N 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108010084313 CD58 Antigens Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102100030386 Granzyme A Human genes 0.000 description 1
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 1
- 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 1
- 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000687438 Homo sapiens Prolactin Proteins 0.000 description 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 101150113776 LMP1 gene Proteins 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 1
- 101100333728 Mus musculus Ercc8 gene Proteins 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- 101100201916 Mus musculus Rtl1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 101800000849 Tachykinin-associated peptide 2 Proteins 0.000 description 1
- 206010043395 Thalassaemia sickle cell Diseases 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 101710113649 Thyroid peroxidase Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011037 discontinuous sequential dilution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000010502 episomal replication Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 108010028930 invariant chain Proteins 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960000554 metrizamide Drugs 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000003196 serial analysis of gene expression Methods 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 108010032486 splenopentin Proteins 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Abstract
The present invention provides compositions and methods for enhancing sitespecific in vivo delivery of tumor associated antigens. Thus, in one aspect, this invention provides a method of recruiting antigen presenting cells (APCs) to a predetermined site in a subject. Methods of augmenting transduction of a transgene in vivo are also provided by this invention.
Description
COMPOSITIONS AND METHODS FOR ENHANCED ANTIGEN
DELIVERY TO ANTIGEN PRESENTING CELLS IN VIVO
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority under 35 U.S.C. ~ 119(e) to U.S.
Provisional Application No. 60/078,909, filed March 20, 1998, the contents of which are hereby incorporated by reference into the present disclosure.
TECHNICAL FIELD
This invention is in the field of molecular immunology and medicine. In particular, compositions and methods for enhancing site-specific in vivo delivery of tumor associated antigens are provided.
BACKGROUND
In spite of numerous advances in medical research, cancer remains the second leading cause of death in the United States. In the industrialized nations, roughly one in five persons will die of cancer. Traditional modes of clinical care, such as surgical resection, radiotherapy and chemotherapy, have a significant failure rate, especially for solid tumors. Failure occurs either because the initial tumor is unresponsive, or because of recurrence due to regrowth at the original site and/or metastases.
Cellular immunotherapy is emerging as a technologically and intellectually compelling anti-cancer treatment. The generation of an immune response against tumors has been demonstrated in several animal models and has been inferred from reports of spontaneous tumor regression in patients (Stotter and Lotze (1990) Cancer Cells 2:44-55). Cytotoxic T-lymphocyte (CTL) responses can be directed against antigens specifically presented by tumor cells, both in vivo and in vitro, without the need for prior knowledge of the molecular mechanism by which the tumor arose. In animal models, established tumors can be eradicated by the adoptive transfer of T-cells that are specifically immune to the malignant cells (Bean et al. ( 1994) Immunol. Today 15:11-1 S).
The use of gene therapy vectors expressing tumor associated antigens (TAA) has been proposed for the treatment of certain cancers. One of the critical factors in cancer gene therapy is the route of administration of the vector encoding the TAA transgene. Currently, common routes of administration in the mouse include intraperitoneal (i.p.), intramuscular (i.rn.), intravascular (i.v.), subcutaneous (s.c.) and intradermal (i.d.) (Wan et al. (1997) Human Gene Therapy 8:1355-63). The optimal route of administration appears to be dependent upon the type of tumor cell as well the TAA encoded on the transgene.
The current limitation of in vivo administration of TAA-expressing is that they do not suppress growth of actively growing tumors. In other words, when vectors expressing TAAs are administered in vivo prior to the challenge with tumor cells, tumor growth is not suppressed unless the vectors are co-administered with interleukin 2 (IL-2). However, even with the IL-2 supplement, tumor growth is suppressed but not completely inhibited.
Antigen presenting cells (ADCs), a class of cells which includes dendritic cells, monocytes, macrophages, and B cells, are the presumed target for the delivery of TAAs. The TAAs being investigated are, in fact, antigens recognized by cytotoxic T lymphocytes (CTLs). In order to provoke a CTL response, the TAA needs to be presented to cells of the immune system by APCs. Therefore, the APC appears to be the appropriate target for both gene therapy vectors and recombinant TAA proteins. TAA transgenes have been directly delivered to isolated dendritic cells ex vivo, and the transfected dendritic cells are capable of inhibiting actively growing tumors when readministered to the mouse.
Furthermore, tumor growth inhibition is accomplished without IL-2 supplementation.
DELIVERY TO ANTIGEN PRESENTING CELLS IN VIVO
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority under 35 U.S.C. ~ 119(e) to U.S.
Provisional Application No. 60/078,909, filed March 20, 1998, the contents of which are hereby incorporated by reference into the present disclosure.
TECHNICAL FIELD
This invention is in the field of molecular immunology and medicine. In particular, compositions and methods for enhancing site-specific in vivo delivery of tumor associated antigens are provided.
BACKGROUND
In spite of numerous advances in medical research, cancer remains the second leading cause of death in the United States. In the industrialized nations, roughly one in five persons will die of cancer. Traditional modes of clinical care, such as surgical resection, radiotherapy and chemotherapy, have a significant failure rate, especially for solid tumors. Failure occurs either because the initial tumor is unresponsive, or because of recurrence due to regrowth at the original site and/or metastases.
Cellular immunotherapy is emerging as a technologically and intellectually compelling anti-cancer treatment. The generation of an immune response against tumors has been demonstrated in several animal models and has been inferred from reports of spontaneous tumor regression in patients (Stotter and Lotze (1990) Cancer Cells 2:44-55). Cytotoxic T-lymphocyte (CTL) responses can be directed against antigens specifically presented by tumor cells, both in vivo and in vitro, without the need for prior knowledge of the molecular mechanism by which the tumor arose. In animal models, established tumors can be eradicated by the adoptive transfer of T-cells that are specifically immune to the malignant cells (Bean et al. ( 1994) Immunol. Today 15:11-1 S).
The use of gene therapy vectors expressing tumor associated antigens (TAA) has been proposed for the treatment of certain cancers. One of the critical factors in cancer gene therapy is the route of administration of the vector encoding the TAA transgene. Currently, common routes of administration in the mouse include intraperitoneal (i.p.), intramuscular (i.rn.), intravascular (i.v.), subcutaneous (s.c.) and intradermal (i.d.) (Wan et al. (1997) Human Gene Therapy 8:1355-63). The optimal route of administration appears to be dependent upon the type of tumor cell as well the TAA encoded on the transgene.
The current limitation of in vivo administration of TAA-expressing is that they do not suppress growth of actively growing tumors. In other words, when vectors expressing TAAs are administered in vivo prior to the challenge with tumor cells, tumor growth is not suppressed unless the vectors are co-administered with interleukin 2 (IL-2). However, even with the IL-2 supplement, tumor growth is suppressed but not completely inhibited.
Antigen presenting cells (ADCs), a class of cells which includes dendritic cells, monocytes, macrophages, and B cells, are the presumed target for the delivery of TAAs. The TAAs being investigated are, in fact, antigens recognized by cytotoxic T lymphocytes (CTLs). In order to provoke a CTL response, the TAA needs to be presented to cells of the immune system by APCs. Therefore, the APC appears to be the appropriate target for both gene therapy vectors and recombinant TAA proteins. TAA transgenes have been directly delivered to isolated dendritic cells ex vivo, and the transfected dendritic cells are capable of inhibiting actively growing tumors when readministered to the mouse.
Furthermore, tumor growth inhibition is accomplished without IL-2 supplementation.
It is desirable, from a clinical standpoint, to deliver the tumor antigen to the patient's APCs in vivo rather than first isolating APCs for transfection and subsequent readministration. At the current time, however, in vivo delivery of the TAA transgene to APC is not as effective in suppressing tumor cell growth as delivery of the TAA transgene to APCs ex vivo. There are a number of possible explanations as to why in vivo transfections of APCs is not as efficacious as ex vivo transfection. First, there may not be many APCs in the region where the gene therapy vector is administered. Second, the number of copies of the gene therapy vector per APC may also be too low for effective transfection. Third, the APCs at the site of administration may be at an inappropriate state of maturity for effective transfection with a TAA transgene. As a result, the TAA may not be presented to the immune system in the manner that produced effective tumor growth inhibition.
DISCLOSURE OF THE INVENTION
The present invention provides compositions and methods for enhancing in vivo site-specific delivery of tumor associated antigens. Thus, in one aspect, this invention provides a method of recruiting antigen presenting cells to a predetermined site in a subject by administering to the subject an effective amount of an antigen presenting cell (APC) recruitment or proliferation factor to the predetermined site. The APC recruitment or proliferation factor may be a proinflammatory agent, a chemotactic agent, a growth factor or a mitogenic factor, and may be administered as a protein, a peptide or in a gene delivery vehicle.
In a preferred embodiment, the APC recruitment or proliferation factor is granulocyte-macrophage colony-stimulating factor (GM-CSF), Sepragel, IL4 or macrophage inflammatory protein 3a. In another embodiment, a growth factor, a cytokine, a co-stimulatory molecule and/or a mitogenic factor can also be administered with the APC recruitment or proliferation factor.
In another aspect, the present invention provides a method to enhance the presentation of an antigen into antigen presenting cells (APCs) in vivo, by priming a predetermined site in a subject with an effective amount of an APC
recruitment or proliferation factor, and administering an effective amount of the antigen to the site. The antigen is administered as a protein, a recombinant protein, or a peptide.
Alternatively, the antigen can be administered in the form of an antigne-encoding S gene in a gene delivery vehicle. As such, the invention also encompasses a method to augment transduction of a transgene encoding an antigen into APCs in vivo, by priming a predetermined site in a subject with an effective amount of an APC recruitment or proliferation factor prior to the administration of an effective amount the transgene to the site. In one illustrative aspect, the antigen is a tumor-associated antigen (TAA). In one embodiment, the APC recruitment or proliferation factor is a proinflammatory agent, a chemotactic agent, a growth factor and/or a mitogenic factor. In a preferred embodiment, the APC
recruitment or proliferation factor is selected from the group consisting of granulocyte-macrophage colony stimulating factor (GM-CSF), Sepragel, interleukin 4 (IL4) and macrophage inflammatory protein 3 alpha (IVIIP-3a). In another embodiment, a growth factor, a cytokine, a co-stimulatory molecule and/or a mitogenic factor can be administered with the antigen including TAA.
MODES FOR CARRYING OUT THE INVENTION
Throughout this disclosure, various publications, patents and published patent specifications are referenced by an identifying citation. The disclosures of these publications, patents and published patent specifications are hereby incorporated by reference into the present disclosure to more fully describe the state of the art to which this invention pertains.
General Techniques The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, such as, "Molecular Cloning: A Laboratory Manual," second edition (Sambrook et al., 1989); "Oligonucleotide Synthesis" (M.J. Gait, ed., 1984); "Animal Cell Culture" (R.I. Freshney, ed., 1987); the series "Methods in Enzymology"
(Academic Press, Inc.); "Handbook of Experimental Immunology" (D.M. Weir &
C.C. Blackwell, eds.); "Gene Transfer Vectors for Mammalian Cells" (J.M.
Miller & M.P. Calos, eds., 1987); "Current Protocols in Molecular Biology" (F.M.
Ausubel et al., eds., 1987, and periodic updates); "PCR: The f olymerase Chain Reaction," (Mullis et al., eds., 1994); "Current Protocols in Immunology"
(J.E.
Coligan et al., eds., 1991 ).
Definitions As used herein, certain terms may have the following defined meanings.
As used in the specification and claims, the singular form "a," "an" and "the" include plural references unless the context clearly dictates otherwise.
For example, the term "a cell" includes a plurality of cells, including mixtures thereof.
The terms "cancer," "neoplasm," and "tumor," used interchangeably and in either the singular or plural form, refer to cells that have undergone a malignant transformation that makes them pathological to the host organism. Primary cancer cells (that is, cells obtained from near the site of malignant transformation) can be readily distinguished from non-cancerous cells by well-established techniques, particularly histological examination. The definition of a cancer cell, as used herein, includes not only a primary cancer cell, but any cell derived from a cancer cell ancestor. This includes metastasized cancer cells, and in vitro cultures and cell lines derived from cancer cells. When referring to a type of cancer that normally manifests as a solid tumor, a "clinically detectable" tumor is one that is detectable on the basis of tumor mass; e.g., by such procedures as CAT scan, magnetic resonance imaging (MRI), X-ray, ultrasound or palpation. Biochemical or immunologic findings alone may be insufficient to meet this definition.
Tumor cells often express antigens which are tumor specific.
The term "tumor associated antigen" or "TAA" refers to an antigen that is associated with or specific to a tumor. Localized increases in dendritic cell populations can be achieved by inducing either migration or proliferation of these cells. Recombinant adenoviral vectors expressing the melanoma TAAs such as gp 100 (Ad2/hugp 100 v2), MART 1 (Ad2/MART 1 ), TRP 1 (Ad2/TRP 1 ) and TRP2 (Ad2fTRP2) were made at Genzyme Corporation. The cationic lipids, GL67 and GL 89) and DNA vaccines expressing gp 100 (pCF 1 hugp 100), TRP 1 (pCF 1 TRP 1 ), and TRP2 (pCF 1 TRP2) were made at Genzyme Corporation.
The term "immune effector cells" refers to cells that specifically recognize an antigen present, for example on a neoplastic or tumor cell. For the purposes of this invention, immune effector cells include, but are not limited to, B
cells, monocytes, macrophages, NK cells and T cells such as cytotoxic T lymphocytes (CTLs), for example CTL lines, CTL clones, and CTLs from tumor, inflammatory, or other infiltrates. "T-lymphocytes" denotes lymphocytes that are phenotypically CD3+, typically detected using an anti-CD3 monoclonal antibody in combination with a suitable labeling technique. The T-lymphocytes of this invention are also generally positive for CD4, CDB, or both. The term "naive"
immune effector cells refers to immune effector cells that have not encountered antigen and is intended to by synonymous with unprimed and virgin. "Educated"
refers to immune effector cells that have interacted with an antigen such that they differentiate into an antigen-specific cell.
An "effective amount" is an amount sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, applications or dosages. The proteins, peptides and polynucleotides of the present invention may be administered or applied transdermally, orally, subcutaneously, intramuscularly, intravenously, intradermally or parenterally. For purposes of this invention, an effective amount of the protein, peptide or polynucleotide is that amount which provokes an antigen-specific immune response in the subject.
The terms "polynucleotide" and "nucleic acid molecule" are used interchangeably to refer to polymeric forms of nucleotides of any length. The polynucleotides may contain deoxyribonucleotides, ribonucleotides, and/or their analogs. Nucleotides may have any three-dimensional structure, and may perform any function, known or unknown. The term "polynucleotide" includes single-, double-stranded and triple helical molecules.
"Oligonucleotide" refers to polynucleotides of between about 5 and about 100 nucleotides of single- or double-stranded DNA. Oligonucleotides are also known as oligomers or oligos and may be isolated from genes, or chemically synthesized by methods known in the art. A "primer" refers to an oligonucleotide, usually single-stranded, that provides a 3'-hydroxyl end for the initiation of enzyme-mediated nucleic acid synthesis.
The following are non-limiting embodiments of polynucleotides: a gene or gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A nucleic acid molecule may also comprise modified nucleic acid molecules, such as methylated nucleic acid molecules and nucleic acid molecule analogs. Analogs of purines and pyrimidines are known in the art, and include, but are not limited to, aziridinycytosine, 4-acetylcytosine, S-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethyl-aminomethyluracil, inosine, N6-isopentenyladenine, 1-methyladenine, 1-methylpseudouracil, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, pseudouracil, 5-pentylnyluracil and 2,6-diaminopurine. The use of uracil as a substitute for thymine in a deoxyribonucleic acid is also considered an analogous form of pyrimidine. By way of example only and not to limit this invention, the polynucleotides encode a peptide, a ribozyme or an antisense sequence.
The terms "protein," "oligopeptide," "polypeptide" and "peptide" are used interchangeably to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the def nition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modification known in the art.
A "subject" is a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, marines, simians, humans, farm animals, sport animals, and pets. The term "predetermined site" refers to the region of the subject into which it is intended that the methods described herein will be practices. Preferably, the predetermined site is a region that is naturally rich in antigen presenting cells such as skin.
By "priming" is meant any treatment or preparation causing a desired result. For purposes of the this invention, priming a site means preparing that site for administration of transgene by first recruiting antigen presenting cells to that site.
The terms "antigen presentation cells" or "APCs" includes both intact, whole cells as well as other molecules which are capable of inducing the presentation of one or more antigens, preferably with class I MHC molecules.
Examples of suitable APCs are discussed in detail below and include, but are not limited to, whole cells such as macrophages, dendritic cells and B cells.
Dendritic cells (DCs) are potent antigen-presenting cells (APCs). It has been shown that DCs provide all the signals required for T cell activation and proliferation. These signals can be categorized into two types. The first type, which gives specificity to the immune response, is mediated through interaction between the T-cell receptor/CD3 ("TCR/CD3") complex and an antigenic peptide presented by a major histocompatibility complex ("MHC") class I or II protein on the surface of APCs. This interaction is necessary, but not sufficient, for T
cell activation to occur. In fact, without the second type of signal, the first type of signals can result in T cell anergy. The second type of signal, called a costimulatory signal, is neither antigen-specific nor MHC-restricted, and can lead to a full proliferation response of T cells and induction of T cell effector functions in the presence of the first type of signals.
DCs are minor constituents of various immune organs such as spleen, thymus, lymph node, epidermis, and peripheral blood. For instance, DCs represent merely about 1 % of crude spleen (Steinman et al. ( 1979) J. Exp.
Med.
149:1) or epidermal cell suspensions (Schuler et al. (1985) J. Exp. Med.
161:526;
and Romani et al. (1989) J. Invest. Dermatol. 93:600), and 0.1-1% of mononuclear cells in peripheral blood (Freudenthal et al. (1990) Proc. Natl. Acad. Sci.
USA
87:7698). Methods for generating dendritic cells from peripheral blood or bone marrow progenitors have been described (Inaba et al. (1992) J. Exp. Med.
175:1157; Inaba et al. (1992) J. Exp. Med. 176:1693-1702; Romani et al. (1994) J. Exp. Med. 180:83-93; Sallusto et al. (1994) J. Exp. Med.179:1109-1118;
Bender et al. (1996) J. Imm. Methods 196:121-135; and Rornani et al. (1996) J.
Imm. Methods 196:137-151).
"Co-stimulatory molecules" are molecules involved in the interaction between receptor-ligand pairs expressed on the surface of antigen presenting cells and T cells. "Co-stimulatory activity" was originally defined as an activity provided by bone-marrow-derived accessory cells such as macrophages and dendritic cells, the so called "professional" APCs. Several molecules have been shown to enhance co-stimulatory activity. These are heat stable antigen (HSA) (Liu Y. et al. (1992) J. Exp. Med.175:437), chondroitin sulfate-modified MHC
invariant chain (Ii-CS) (Naujokas M.F. et al. (1993) Cell 74:257), intracellular adhesion molecule 1 (ICAM-1) (Van Seventer G.A. (1990) J. ImmunoL
144:4579), B7-1 and B7-2/B70 (Schwartz R.H. (1992) Cell 71:1065) and B7's counter-receptor CD28 or CTLA-4 on T cells (Freeman et al. (1993) Science 262:909; Young et al. (1992) J. Clin. Invest 90: 229; and Nabavi et al. (1992) Nature 360:266). Other important co-stimulatory molecules are CD40, CD54, ~CD80, CD86. As used herein, the term "co-stimulatory molecule" encompasses any single molecule or combination of molecules which, when acting together with a peptide/MHC complex bound by a TCR on the surface of a T cell, provides a co-stimulatory effect which achieves activation of the T cell that binds the peptide. The term thus encompasses B7, or other co-stimulatory molecules) on an antigen-presenting matrix such as an APC, fragments thereof (alone, complexed with another molecule(s), or as part of a fusion protein) which, together with peptide/MHC complex, binds to a cognate ligand and results in activation of the T cell when the TCR on the surface of the T cell specifically binds the peptide. Co-stimulatory molecules are commercially available from a variety of sources, including, for example, Beckman Coulter. It is intended, although not always explicitly stated, that molecules having similar biological activity as wild-type or purified co-stimulatory molecules (e.g., recombinantly produced or muteins thereof) are intended to be used within the spirit and scope of the invention.
The terms "antigen presenting cell recruitment or proliferation factors" or "APC recruitment or proliferation factors" includes both intact, whole cells as well as other molecules which are capable of recruiting antigen presenting cells.
APC recruitment or proliferation factors include "proinflammatory agents,"
"chemotactic agents," "growth factors" and "mitogenic agents." Numerous mediators of dendritic cell migration and proliferation have been described in both in vitro and in vivo models. Examples of suitable APC factors include molecules such as interleukin 4 (IL4), granulocyte macrophage colony stimulating factor (GM-CSF), Sepragel and macrophage inflammatory protein 3 alpha (MIP3a).
Schering-Plough, Genzyme, Immunex. Other APC recruitment or proliferation factors include cytokines such as IL-2, stem cell factor (SCF), IL-3, IL-6, IL-12, G-CSF, GM-CSF, IL-la, IL-11, MIP-la, LIF, c-kit ligand, TPO, and flt3 ligand.
Cytokines are commercially available from several vendors such as, for example, Genentech (South San Francisco, CA), Amgen (Thousand Oaks, CA) and Immunex (Seattle, WA). It is intended, although not always explicitly stated, that t molecules having similar biological activity as wild-type or purified APC
recruitment or proliferation factors (e.g., recombinantly produced) are intended to be used within the spirit and scope of the invention.
In vitro, dendritic cell chemotaxis is induced by macrophage-derived chemokine (MDC) (Godiska et al. ( 1997) J. Exp. Med. 185:1595:1604), formyl peptides, CSa, and chemokines such as monocyte chemotactic protein (MCP)-3 and RANTES (Morelli et al. (1996) Immunology 89:126-134; Sozzani et al.
(1995) J. Immunol. 155:3292-3295). However, human dendritic cell chemotaxis is not induced by IL-8, IL-10, MCP-1, and MCP-2 in vitro (Sozzani et al.
(1995) supra). The proliferation and maturation of cultured dendritic cells is promoted by granulocyte macrophage-colony stimulating factor (GM-CSF) GM-CSF (Caux et al. (1992) Nature 360:258-261; Witmer-Pack et al. (1987) J. Exp. Med.
166:1484-1498). In vivo, the number of Langerhans cells, a type of dendritic cell, has been increased in response to GM-CSF in the skin (Kaplan et al. (1992) J.
1 S Exp. Med.175:1717); O'Sullivan et al. (1997) Exp. Dermatol. 6:236-242) and in the lungs (Tazi et al. (1993) J. Clin. Invest. 91:566-576). In addition, Langerhans cell recruitment or proliferation to the skin has been induced using splenopentin (a pentapeptide hormone) (Gruner et al. (1990) Arch. Dermatol. Res. 281:526-529).
Recombinant marine GM-CSF (mGM-CSF) (Genzyme Corporation, Cambridge, MA) is a glycosylated polypeptide (23-29kD) (Burgess et al. (1977) J.
Biol. Chem. 252:1998-2003) of 142 amino acids (Gough et al. (1985) Nature 309:763-767). Human GM-CSF (hGM-CSF) is a glycoprotein of 22kD (Gasson et al. (1984) Science 226:1339-1342) of 144 amino acids (along et al. {1985) Cancer Cells 3:235-242). The homology between marine and human GM-CSF is 60% and there is no species cross reactivity. Recombinant prolactin (PRL) (Genzyme Corporation, Cambridge, MA) is a protein with a molecular weight of about 25 kD consisting of 205 amino acids. Sepragel (Genzyme Corporation, Cambridge, MA) is a cross-linked hyaluronic acid gel. Recombinant adenoviral vectors expressing mGM-CSF (Ad2/cmvGMCSFF9ix) and human prolactin (Ad2/EV/PRL) were made at Genzyme (Framingham, MA).
A "gene delivery vehicle" is defined as any molecule that can carry inserted polynucleotides into a host cell. A "transgene" is the term given to the polynucleotide carried by the gene delivery vehicle. The term "transduction"
refers to the transfer of polynucleotides into a host cell. Examples of gene delivery vehicles are liposomes, viruses, such as baculovirus and retrovirus, bacteriophage, cosmid, plasmid, fungal vectors and other recombination vehicles typically used in the art which have been described for expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple protein expression.
A "viral vector" is defined as a recombinantly produced virus or viral particle that comprises a polynucleotide to be delivered into a host cell, either in vivo, ex vivo or in vitro. Examples of viral vectors include retroviral vectors, adenovirus vectors, adeno-associated virus vectors and the like.
In aspects where gene transfer is mediated by a retroviral vector, a vector construct refers to the polynucleotide comprising the retroviral genome or part thereof, and a therapeutic gene. As used herein, "retroviral mediated gene transfer" or "retroviral transduction" carnes the same meaning and refers to the process by which a gene or nucleic acid sequences are stably transferred into the host cell by virtue of the virus entering the cell and integrating its genome into the host cell genome. The virus can enter the host cell via its normal mechanism of infection or be modified such that it binds to a different host cell surface receptor or ligand to enter the cell. Retroviruses carry their genetic information in the form of RNA; however, once the virus infects a cell, the RNA is reverse-transcribed into the DNA form which integrates into the genomic DNA of the infected cell.
The integrated DNA form is called a provints.
In aspects where gene transfer is mediated by a DNA viral vector, such as a adenovirus (Ad) or adeno-associated virus (AAA, a vector construct refers to the polynucleotide comprising the viral genome or part thereof, and a therapeutic gene. Adenoviruses (Ads) are a relatively well characterized, homogenous group of viruses, including over 50 serotypes. (see, e.g., WO 95/27071 ) Ads are easy to grow and do not require integration into the host cell genome. Recombinant Ad-derived vectors, particularly those that reduce the potential for recombination and generation of wild-type virus, have also been constructed. (see, e.g. WO
95/00655; WO 95/11984). Wild-type AAV has high infectivity and specificity integrating into the host cells genome. (Hermonat and Muzyczka (1984) Proc.
Natl. Acad. Sci. USA 81:6466-6470; Lebkowski et al. (1988} Mol. Cell. Biol.
8:3988-3996).
Vectors that contain both a promoter and a cloning site into which a polynucleotide can be operatively linked are well known in the art. Such vectors are capable of transcribing RNA in vitro or in vivo, and are commercially available from sources such as Stratagene (La Jolla, CA) and Promega Biotech (Madison, WI). In order to optimize expression and/or in vitro transcription, it may be necessary to remove, add or alter 5' and/or 3' untranslated portions of the clones to eliminate extra, potential inappropriate alternative translation initiation codons or other sequences that may interfere with or reduce expression, either at the level of transcription or translation. Alternatively, consensus ribosome binding sites can be inserted immediately S' of the start codon to enhance expression.
Among these are several non-viral vectors, including DNA/liposome complexes, and targeted viral protein DNA complexes. To enhance delivery to a cell, the nucleic acid or proteins of this invention can be conjugated to antibodies or binding fragments thereof which bind cell surface antigens, e.g., TCR, CD3 or CD4. Liposomes that also comprise a targeting antibody or fragment thereof can be used in the methods of this invention. This invention also provides the targeting complexes for use in the methods disclosed herein.
Polynucleotides are inserted into vector genomes using methods well known in the art. For example, insert and vector DNA can be contacted, under suitable conditions, with a restriction enzyme to create complementary ends on each molecule that can pair with each other and be joined together with a ligase.
Alternatively, synthetic nucleic acid linkers can be ligated to the termini of restricted polynucleotide. These synthetic linkers contain nucleic acid sequences that correspond to a particular restriction site in the vector DNA.
Additionally, an oligonucleotide containing a termination colon and an appropriate restriction site can be ligated for insertion into a vector containing, for example, some or all of the following: a selectable marker gene, such as the neomycin gene for selection of stable or transient transfectants in mammalian cells; enhancer/promoter sequences from the immediate early gene of human CMV for high levels of transcription; transcription termination and RNA processing signals from SV40 for mRNA stability; SV40 polyoma origins of replication and ColEl for proper episomal replication; versatile multiple cloning sites; and T7 and SP6 RNA
promoters for in vitro transcription of sense and antisense RNA. Other means are well known and available in the art.
As used herein, "expression" refers to the process by which polynucleotides are transcribed into mRNA and translated into peptides, polypeptides, or proteins. If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA, if an appropriate eukaryotic host is selected. Regulatory elements required for expression include promoter sequences to bind RNA polymerise and transcription initiation sequences for ribosome binding. For example, a bacterial expression vector includes a promoter such as the lac promoter and for transcription initiation the Shine-Dalgarno sequence and the start colon AUG (Sambrook et al. (1989) supra ). Similarly, an eukaryotic expression vector includes a heterologous or homologous promoter for RNA polymerise II, a downstream polyadenylation signal, the start colon AUG, and a termination colon for detachment of the ribosome. Such vectors can be obtained commercially or assembled by the sequences described in methods well known in the art, for example, the methods described below for constructing vectors in general.
"Host cell" is intended to include any individual cell or cell culture which can be or have been recipients for vectors or the incorporation of exogenous nucleic acid molecules, polynucleotides and/or proteins. It also is intended to include progeny of a single cell, and the progeny may not necessarily be completely identical (in morphology or in genomic or total DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation.
The cells may be prokaryotic or eukaryotic, and include but are not limited to bacterial cells, yeast cells, animal cells, and mammalian cells, e.g., marine, rat, simian or human.
An "antibody" is an immunoglobulin molecule capable of binding an antigen. As used herein, the term encompasses not only intact immunoglobulin molecules, but also anti-idiotypic antibodies, mutants, fragments, fusion proteins, humanized proteins and modifications of the immunoglobulin molecule that comprise an antigen recognition site of the required specificity.
A "composition" is intended to mean a combination of active agent and another compound or composition, inert (for example, a detectable agent or label) or active, such as an adjuvant.
A "pharmaceutical composition" is intended to include the combination of an active agent with a carrier, inert or active, making the composition suitable for diagnostic or therapeutic use in vitro, in vivo or ex vivo.
As used herein, the term "pharmaceutically acceptable carnet"
encompasses any of the standard pharmaceutical carnets, such as a phosphate buffered saline solution, water, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carnets, stabilizers and adjuvants, see Martin, xi;MiNGTON'S PHAi~t. SCI., 15th Ed. (Mack Publ. Co., Easton (1975)).
As used herein, the term "comprising" is intended to mean that the compositions and methods include the recited elements, but not excluding others.
"Consisting essentially of when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination.
Thus, a composition consisting essentially of the elements as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like. "Consisting of shall mean excluding more than trace elements of other ingredients and substantial method steps for administering the compositions of this invention. Embodiments defined by each of these transition terms are within the scope of this invention.
This invention provides a method to enhance the recruitment or increase the number of APCs to a predetermined site or location in a subject by administering to the subject an effective amount of an APC recruitment or proliferation factor and under conditions which favor the recruitment or increase in the number of APC to the site of administration. In one aspect, the factor is formulated for slow release (i.e., in a sponge or liposome) so as to create a sustained localized concentration of the APC recruitment or proliferation factor.
The recruitment or proliferation factor is, in some embodiments, GM-CSF or Supragel. The recruitment or proliferation factor also includes, but is not limited to, biological equivalents of these protein such as amino acid sequences having conservative amino acid substitutions and fusion proteins. This may include yet unidentified proteins which may be assayed in the animal model presented below.
The biological activity of an equivalent protein can be assayed by using the animal model detailed below.
The recruitment or proliferation factor of this invention also can be administered as a polynucleotide or gene coding for the factor. These polynucleotides can be delivered using conventional gene therapy delivery vehicles, vectors and methods as provided below. Either of these means of delivering the recruitment or proliferation factor of this invention can be further modified by the co-administration of a growth factor, a cytokine, a co-stimulatory molecule or a mitogenic molecule, prior to, subsequently to or concurrently with the recruitment or proliferation factor. Alternatively, a host cell can be transduced with genes) encoding these molecules which is then administered to the subject.
In one aspect of the invention, the host cell containing the gene{s) coding for the ctyokine and/or co-stimulatory molecule is a professional antigen-presenting cell such as a dendritic cell which includes, but is not limited to, a pulsed dendritic cell, a dendritic cell hybrid or an antigen-presenting foster cell.
Presentation of the antigens such as tumor associated antigens by the APCs elicits a strong immune response resulting in destruction of tumor cells by antigen-specific immune effector cells such as cytotoxic T lymphocyte cells (CTLs). Thus, in one aspect, this is achieved by recruiting antigen presenting cells to a predetermined site in a subject, by administering an effective amount of an APC recruitment or proliferation factor. The induction of the CTL response is one method to assay for a positive response to the therapy and a means to confirm the biological activity of new factors useful in the methods of this invention. The presence of a large number of T-cells in a tumor has been correlated with a prognostically favorable outcome in some cases (Whiteside and Parmiani (1994) Cancer Immunol. Immunother. 39:15-21 ). It has been shown that implantation of polyurethane sponges containing irradiated tumor cells can efficiently trap anti-tumor CTLs (4-times greater than lymph fluid, 50-times greater than spleen or peripheral blood). Woolley et al. (1995) Immmunology 84:55-63. Following activation with T-cell cytokines in the presence of their appropriately presented recognition antigen, TILs proliferate in culture and acquire potent anti-tumor cytolytic properties. Weidmann et al. (1994) Cancer Immunol. Immunother. 39:1-14. Assays to determine T cell response are well known in the art and any method that will compare T cell number prior to, and subsequent to therapy can be utilized. In addition, the induction of co-stimulatory molecules by the polynucleotide could also stimulate anergic or low affinity self reactive CTL
clones. Methods to assay for CTL clones include: standard s'Cr release assay as described in Kawakami et al. (1988) J. Exp. Med. 168:2183-91. Briefly, cytotoxic T cells are added to target cells previously loaded with s'Cr and one measures the release of 5'Cr from the lysed target cells. Cytokine release assay can be used as described in Kawakami et al. (1994) Proc. Natl. Acad. Sci. USA 91:3515-19.
Briefly, cytotoxic T cells are added to target cells and one measures the amount of IFNY released by ELISA. To measure the relative proportion of immune effector cells within a mixed population that recognize a particular target, the Enzyme-LInked immunoSPOT (ELISPOT) assay is employed as described in Czerkinsky et al. ( 1988) J. Immunol. Methods 110:29-36. Briefly, 96 well nitrocellulose-bottomed plates are coated with an anti-cytokine antibody, generally anti-interferon-y. Target cells and immune effector cells such as cytotoxic T cells (CTLs) are added to wells. Cytokine released from the CTLs is captured by the anti-interferon-y antibody and quantitated using a standard ELISA format.
In another aspect, the present invention provides a method to enhance presentation of an antigen into antigen presenting cells (APCs) in vivo, by priming a predetermined site in a subject with an effective amount of an APC
recruitment or proliferation factor, and administering an effective amount of the antigen to the site. The antigen is administered as a protein, a recombinant protein, or a peptide.
This invention further provides a method to augment transduction of transgenes into APCs in vivo, by priming a predetermined site in a subject with an effective amount of an APC recruitment or proliferation factor and administering an effective amount of the transgene, which may be a tumor associated antigen.
The antigen of this vaccine may be an altered antigen or heterologous (i.e., allogeneic or a homolog from a isolated species, e.g., a marine antigen administered to a human patient). It may be a previously characterized tumor-associated antigens such as gp100 (Kawakami et al. (1997) Intern. Rev. Immunol.14:173-192);
MUC-1 (Henderson et al. (1996) Cancer Res. 56:3763-3770); MART-1 (Kawakami et al. (1994) Proc. Natl. Acad. Sci. USA 91:3515-3519; Kawalcami et al. (1997) Intern. Rev. Immunol.14:173-192; and Ribas et al. (1997) Cancer Res.
57:2865-2869); HER-2/neu (U.S. Patent No. 5,550,214), MAGE
(PCT/US92/04354); HPV16, 18E6 and E7 (Ressing et al. (1996) Cancer Res.
56(1):582-588; Rstifo (1996) Curr. Op. Immunol. 8:658-663; Stern (1996) Adv.
Cancer Res. 69:175-211; Tindle et al. (1995) Clin. Exp. Immunol. 101:265-271;
and van Driel et al. (1996) Annals of Medicine 28:471-477); CEA (LT.S. Patent No. 5,274,087); PSA (Lundwall A. (1989) Biochem. Biophys. Research Comm.
161:1151-59); prostate membrane specific antigen (PSMA) (Israeli et al. (1993) Cancer Research 53:227-30); tyrosinase (U.S. Patent Nos. 5,530,096 and 4,898,814; Brichard et al. (1993) J. Exp. Med.178:489-49); tyrosinase related proteins 1 or 2 (TRP-1 and TRP-2); NY-ESO-1 (Chen et al. (1997) Proc. Natl.
Acad. Sci. USA 94:1914-18); or the GA733 antigen (U.S. Patent No. 5,185,254).
The coding and amino acid sequences of these antigens are available in the art.
For example, human and marine MUC 1 coding sequences are provided under Genbank Accession No. M35093 and M64928.
Biologically equivalent proteins of known antigens also are useful in the methods described herein. These proteins are encoded by polynucleotides that hybridize under stringent conditions to the sequences disclosed in the references described above or known in the art. Alternatively, the proteins are encoded by polynucleotides that are at least 80%, or more preferably, at least 90% or most preferably, at least 95%, identical to the disclosed sequences using as determined using sequence alignment programs and default parameters.
"Hybridization" refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding between the bases of the nucleotide residues. The hydrogen bonding may occur by Watson-Crick base pairing, Hoogstein binding, or in any other sequence-specific manner. The complex may comprise two strands forming a duplex structure, three or more strands forming a mufti-stranded complex, a single self hybridizing strand, or any combination of these. A hybridization reaction may constitute a step in a more extensive process, such as the initiation of a PCR reaction, or the enzymatic cleavage of a polynucleotide by a ribozyme.
Examples of stringent hybridization conditions include: incubation temperatures of about 25°C to about 37°C; hybridization buffer concentrations of about 6 X SSC to about 10 X SSC; formamide concentrations of about 0% to about 25%; and wash solutions of about 6 X SSC. Examples of moderate hybridization conditions include: incubation temperatures of about 40°C
to about 50°C; buffer concentrations of about 9 X SSC to about 2 X SSC;
formamide concentrations of about 30% to about 50%; and wash solutions of about 5 X SSC
WOl9/47179 PCT/US99/06071 to about 2 X SSC. Examples of high stringency conditions include: incubation temperatures of about 55°C to about 68°C; buffer concentrations of about 1 X
SSC to about 0.1 X SSC; fortnamide concentrations of about 55% to about 75%;
and wash solutions of about 1 X SSC, 0.1 X SSC, or deionized water. In general, hybridization incubation times are from S minutes to 24 hours, with 1, 2, or more washing steps, and wash incubation times are about 1, 2, or 15 minutes. SSC is 0.1 S M NaCI and I 5 mM citrate buffer. It is understood that equivalents of SSC
using other buffer systems can be employed.
A polynucleotide or polynucleotide region (or a polypeptide or polypeptide region} has a certain percentage (for example, 80%, 85%, 90%, or 95%) of "sequence identity" to another sequence means that, when aligned, that percentage of bases (or amino acids) are the same in comparing the two sequences. This alignment and the percent homology or sequence identity can be determined using software programs known in the art, for example those described in CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (F.M. Ausubel et al., eds., 1987) Supplement 30, section 7.7.18, Table 7.7.1. Preferably, default parameters are used for alignment. A preferred alignment program is BLAST, using default parameters. In particular, preferred programs are BLASTN and BLASTP, using the following default parameters: Genetic code = standard;
filter = none; strand = both; cutoff= 60; expect =10; Matrix = BLOSUM62;
Descriptions = 50 sequences; sort by = HIGH SCORE; Databases = non-redundant, GenBank + EMBL + DDBJ + PDB + GenBank CDS translations +
SwissProtein + SPupdate + PIR. Details of these programs can be found at the following Internet address: http://www.ncbi.nlm.nih.gov/cgi-bin/BLAST.
It also may be a yet undetermined antigen identified by the methods described herein or well known to those of skill in the art.
The antigen can be administered as a protein, a recombinant protein, a peptide, or, alternatively, a polynucleotide in a gene delivery vehicle.
Furthermore, the invention provides a method for cloning the cDNA and genomic DNA encoding novel recruitment or proliferation factors identified by this invention, by generating degenerate oligonucleotides probes or primers based on the sequence of the epitope. Compositions comprising the nucleic acid and a carrier, such as a pharmaceutically acceptable carrier, a solid support or a detectable label, are further provided by this method as well as methods for S detecting the sequences in a sample using methods such as Northern analysis, Southern analysis and PCR.
Further provided by this invention are therapeutic and diagnostic oligopeptide sequences determined according to the foregoing methods.
Compositions comprising the oligopeptide sequence and a carrier, such as a pharmaceutically acceptable Garner, a solid support or a detectable label, are further provided by this method as well as methods for detecting the oligopeptide sequence in a sample using methods such as Western analysis and ELISA.
Harlow and Lane (1988), supra.
Materials and Methods Identification of Tumor Associated Antigens Any conventional method, e.g., subtractive library, comparative Northern and/or Western blot analysis of normal and tumor cells, Serial Analysis of Gene Expression (LT.S. Patent No. 5,695,937) and Solid PHase Epitope REcovery ("SPHERE," described in PCT WO 97/35035), can be used to identify putative antigens for use in the subject invention.
Expression cloning also can be used. This methodology, as described in Kawakami et al. (1994) Proc. Natl. Acad. Sci. USA 91:3515-19, can be used to identify a novel tumor-associated antigen. Briefly, a library of cDNAs corresponding to mRNAs derived from tumor cells is cloned into an expression vector and introduced into target cells which are subsequently incubated with cytotoxic T cells. One identifies pools of cDNAs that are able to stimulate the CTL and through a process of sequential dilution and re-testing of less complex pools of cDNAs one is able to derive unique cDNA sequences that are able to stimulate the CTL and thus encode the cognate tumor antigen.
SAGE analysis involves identifying nucleotide sequences expressed in the antigen-expressing cells. Briefly, SAGE analysis begins with providing complementary deoxyribonucleic acid (cDNA) from ( 1 ) the antigen-expressing population and (2) cells not expressing that antigen. Both cDNAs can be linked to primer sites. Sequence tags are then created, for example, using the appropriate primers to amplify the DNA. By measuring the differences in these tags between the two cell types, sequences which are aberrantly expressed in the antigen-expressing cell population can be identified.
Alternatively, muteins of the antigen as well as allogeneic and antigens from a different species, of previously characterized antigens are useful in the subject invention. MART1 and gp100 are melanocyte differentiation antigens specifically recognized by HLA-A2 restricted tumor-infiltrating lymphocytes (TILs) derived from patients with melanoma, and appear to be involved in tumor regression (Kawakami, Y. et al. (1994) Proc. Natl. Acad. Sci. USA 91:6458-62;
Kawakami, Y. et al. (1994) Proc. Natl. Acad. Sci. USA 91:91:3515-9). Recently, the mouse homolog of human MART-1 has been isolated. The full-length open reading frame of the mouse MART1 consists of 342 bp, encoding a protein of 113 amino acid residues with a predicted molecular weight of ~13 kDa. Alignment of human and marine MART1 amino acid sequences showed 68.6% identity.
The marine homologue of gp100 has also been identified. The open reading frame consists of 1,878 bp, predicting a protein of 626 amino acid residues which exhibits 75.5% identity to human gp100.
SPHERE, described in PCT WO 97/35035, is a method that will identify wild-type or native antigens as well as provide altered antigens. SPHERE is an empirical screening method for the identification of MHC Class I-restricted CTL
epitopes that utilizes peptide libraries synthesized on a solid support (e.g., plastic beads) where each bead contains approximately 200 picomoles of a unique peptide that can be released in a controlled manner. The synthetic peptide library is tailored to a particular HLA restriction by fixing anchor residues that confer high-affinity binding to a particular HLA allele (e.g., HLA-A2) but contain a variable TCR epitope repertoire by randomizing the remaining positions.
Roughly speaking, 50 96-well plates with 10,000 beads per well will accommodate a library with a complexity of approximately 5 X 10'. In order to minimize both the number of CTL cells required per screen and the amount of manual manipulations, the eluted peptides can be further pooled to yield wells with any desired complexity. Based on experiments with soluble libraries, it should be possible to screen 10' peptides in 96-well plates (10,000 peptides per well) with as few as 2 X 1 O6 CTL cells. After cleaving a percentage of the peptides from the beads ami incubating them with 5'Cr-labeled APCs (e.g., T2 cells) and the CTL line(s), peptide pools containing reactive species can be determined by measuring StCr-release according to standard methods known in the art. Alternatively, cytokine production (e.g., interferon-Y) or proliferation (e.g., incorporation of 3H-thymidine) assays may be used. After identifying reactive 10,000-peptide mixtures, the beads corresponding to those mixtures are separated into smaller pools and distributed to new 96-well plates (e.g., 100 beads per well).
An additional percentage of peptide is released from each pool and reassayed for activity by one of the methods listed above. Upon identification of reactive peptide pools, the beads corresponding those peptide mixtures are redistributed at 1 bead per well of a new 96-well plate. Once again, an additional percentage of peptide is released and assayed for reactivity in order to isolate the single beads containing the reactive library peptides. The sequence of the peptides on individual beads can be determined by sequencing residual peptide bound to the beads by, for example, N-terminal Edman degradation or other analytical techniques known to those of skill in the art.
In vitro confirmation of the immunogenicity of a putative antigen of this invention can be confirmed using the method described below, which assays for the production of CTLs.
Isolation, Culturing and Expansion of APCs, Including Dendritic Cells Bender et al. (1996) J. Immunol. Meth. 196:121-135 describes a method for generating sizable numbers of mature dendritic cells from nonproliferating r progenitors in human blood. The procedure requires 1 % human plasma in the place of 10% fetal calf serum and involves two steps. The first step or "priming"
phase is a 6-7 day culture of T cell depleted mononuclear cells in medium supplemented with GM-CSF and IL-4. The second step or "differentiation" phase requires the exposure to macrophage conditioned medium.
Romani et al. (1996) J. Immunol. Methods 196:137-151 describes a method to generate human dendritic cells from hematopoietic precursor cells in peripheral blood. A 3 day maturation culture is added to the initial 6-7 day culture in the presence of GM-CSF and IL-4. Human plasma, rather than fetal calf serum and media approved for clinical use are optimal, additional conditions for use in this method.
The following describe additional methods. In one aspect, a large numbers of precommitted APCs already circulating in the bload are isolated. Previous techniques for isolating committed APCs from human peripheral blood have involved combinations of physical procedures such as metrizamide gradients and adherence/nonadherence steps (Freudenthal et al. (1990) PNAS USA 87:7698-7702); Percoll gradient separations (Mehta-Damani et al. ( 1994) J. Immunol.
153:996-1003); and fluorescence activated cell sorting techniques (Thomas R.
et al. (1993) J. Immunol. 151:6840-52).
The APC can be precommitted or mature dendritic cells, which can be isolated from the white blood cell fraction of a mammal, such as a marine, simian or a human (See, e.g., WO 96/23060). The white blood cell fraction can be from the peripheral blood of the mammal. This method includes the following steps:
(a) providing a white blood cell fraction obtained from a mammalian source by methods known in the art such as leukophoresis; (b) separating the white blood cell fraction of step (a) into four or more subfractions by countercurrent centrifugal elutriation; (c) stimulating conversion of monocytes in one or more fractions from step (b) to dendritic cells by contacting the cells with calcium ionophore; (d) identifying the dendritic cell-enriched fraction from step (c);
and (e) collecting the enriched fraction of step (d), preferably at about 4°C. One way to identify the dendritic cell-enriched fraction is by fluorescence-activated cell sorting (FACS). The white blood cell fraction can be treated with calcium ionophore in the presence of other cytokines, such as rhIL-12, rhGM-CSF, or rhIL-4. The cells of the white blood cell fraction can be washed in buffer and suspended in Ca'+/Mg~ free media prior to the separating step. The white blood cell fraction can be obtained by leukapheresis. The dendritic cells can be identified by the presence of at least one of the following markers: HLA-DR, HLA-DQ, or B7.2, and the simultaneous absence of the following markers: CD3, CD14, CD16, 56, 57, and CD 19, 20. Monoclonal antibodies specific to these cell surface markers are commercially available.
More specifically, the method requires collecting an enriched collection of white cells and platelets from leukapheresis that is then further fractionated by countercurrent centrifugal elutriation (CCE} (Abrahamsen, T.G. et aI. (1991) J.
Clin. Apheresis. 6:48-53). Cell samples are placed in a special elutriation rotor.
The rotor is then spun at a constant speed of, for example, 3000 rpm. Once the rotor has reached the desired speed, pressurized air is used to control the flow rate of cells. Cells in the elutriator are subjected to simultaneous centrifugation and a washout stream of buffer that is constantly increasing in flow rate. This results in fractional cell separations based largely but not exclusively on differences in cell size.
Quality control of APC and more specifically DC collection and confirmation of their successful activation in culture is dependent upon a simultaneous multi-color FACS analysis technique which monitors both monocytes and the dendritic cell subpopulation as well as possible contaminant T
lymphocytes. It is based upon the fact that DCs do not express the following markers: CD3 (T cell); CD14 (monocyte); CD16, 56, 57 (NK/LAK cells); CD19, 20 (B cells). At the same time, DCs do express large quantities of HLA-DR, significant HLA-DQ and B7.2 (but little or no B7. I ) at the time they are circulating in the blood (in addition they express Leu M7 and M9, myeloid markers which are also expressed by monocytes and neutrophils).
When combined with a third color reagent for analysis of dead cells, propridium iodide (PI), it is possible to make positive identification of all cell subpopulations (see Table 1 ):
FACS analysis of fresh peripheral cell subpopulations Color #1 Color #2 Color #3 Cocktail HLA-DR _PI
DISCLOSURE OF THE INVENTION
The present invention provides compositions and methods for enhancing in vivo site-specific delivery of tumor associated antigens. Thus, in one aspect, this invention provides a method of recruiting antigen presenting cells to a predetermined site in a subject by administering to the subject an effective amount of an antigen presenting cell (APC) recruitment or proliferation factor to the predetermined site. The APC recruitment or proliferation factor may be a proinflammatory agent, a chemotactic agent, a growth factor or a mitogenic factor, and may be administered as a protein, a peptide or in a gene delivery vehicle.
In a preferred embodiment, the APC recruitment or proliferation factor is granulocyte-macrophage colony-stimulating factor (GM-CSF), Sepragel, IL4 or macrophage inflammatory protein 3a. In another embodiment, a growth factor, a cytokine, a co-stimulatory molecule and/or a mitogenic factor can also be administered with the APC recruitment or proliferation factor.
In another aspect, the present invention provides a method to enhance the presentation of an antigen into antigen presenting cells (APCs) in vivo, by priming a predetermined site in a subject with an effective amount of an APC
recruitment or proliferation factor, and administering an effective amount of the antigen to the site. The antigen is administered as a protein, a recombinant protein, or a peptide.
Alternatively, the antigen can be administered in the form of an antigne-encoding S gene in a gene delivery vehicle. As such, the invention also encompasses a method to augment transduction of a transgene encoding an antigen into APCs in vivo, by priming a predetermined site in a subject with an effective amount of an APC recruitment or proliferation factor prior to the administration of an effective amount the transgene to the site. In one illustrative aspect, the antigen is a tumor-associated antigen (TAA). In one embodiment, the APC recruitment or proliferation factor is a proinflammatory agent, a chemotactic agent, a growth factor and/or a mitogenic factor. In a preferred embodiment, the APC
recruitment or proliferation factor is selected from the group consisting of granulocyte-macrophage colony stimulating factor (GM-CSF), Sepragel, interleukin 4 (IL4) and macrophage inflammatory protein 3 alpha (IVIIP-3a). In another embodiment, a growth factor, a cytokine, a co-stimulatory molecule and/or a mitogenic factor can be administered with the antigen including TAA.
MODES FOR CARRYING OUT THE INVENTION
Throughout this disclosure, various publications, patents and published patent specifications are referenced by an identifying citation. The disclosures of these publications, patents and published patent specifications are hereby incorporated by reference into the present disclosure to more fully describe the state of the art to which this invention pertains.
General Techniques The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, such as, "Molecular Cloning: A Laboratory Manual," second edition (Sambrook et al., 1989); "Oligonucleotide Synthesis" (M.J. Gait, ed., 1984); "Animal Cell Culture" (R.I. Freshney, ed., 1987); the series "Methods in Enzymology"
(Academic Press, Inc.); "Handbook of Experimental Immunology" (D.M. Weir &
C.C. Blackwell, eds.); "Gene Transfer Vectors for Mammalian Cells" (J.M.
Miller & M.P. Calos, eds., 1987); "Current Protocols in Molecular Biology" (F.M.
Ausubel et al., eds., 1987, and periodic updates); "PCR: The f olymerase Chain Reaction," (Mullis et al., eds., 1994); "Current Protocols in Immunology"
(J.E.
Coligan et al., eds., 1991 ).
Definitions As used herein, certain terms may have the following defined meanings.
As used in the specification and claims, the singular form "a," "an" and "the" include plural references unless the context clearly dictates otherwise.
For example, the term "a cell" includes a plurality of cells, including mixtures thereof.
The terms "cancer," "neoplasm," and "tumor," used interchangeably and in either the singular or plural form, refer to cells that have undergone a malignant transformation that makes them pathological to the host organism. Primary cancer cells (that is, cells obtained from near the site of malignant transformation) can be readily distinguished from non-cancerous cells by well-established techniques, particularly histological examination. The definition of a cancer cell, as used herein, includes not only a primary cancer cell, but any cell derived from a cancer cell ancestor. This includes metastasized cancer cells, and in vitro cultures and cell lines derived from cancer cells. When referring to a type of cancer that normally manifests as a solid tumor, a "clinically detectable" tumor is one that is detectable on the basis of tumor mass; e.g., by such procedures as CAT scan, magnetic resonance imaging (MRI), X-ray, ultrasound or palpation. Biochemical or immunologic findings alone may be insufficient to meet this definition.
Tumor cells often express antigens which are tumor specific.
The term "tumor associated antigen" or "TAA" refers to an antigen that is associated with or specific to a tumor. Localized increases in dendritic cell populations can be achieved by inducing either migration or proliferation of these cells. Recombinant adenoviral vectors expressing the melanoma TAAs such as gp 100 (Ad2/hugp 100 v2), MART 1 (Ad2/MART 1 ), TRP 1 (Ad2/TRP 1 ) and TRP2 (Ad2fTRP2) were made at Genzyme Corporation. The cationic lipids, GL67 and GL 89) and DNA vaccines expressing gp 100 (pCF 1 hugp 100), TRP 1 (pCF 1 TRP 1 ), and TRP2 (pCF 1 TRP2) were made at Genzyme Corporation.
The term "immune effector cells" refers to cells that specifically recognize an antigen present, for example on a neoplastic or tumor cell. For the purposes of this invention, immune effector cells include, but are not limited to, B
cells, monocytes, macrophages, NK cells and T cells such as cytotoxic T lymphocytes (CTLs), for example CTL lines, CTL clones, and CTLs from tumor, inflammatory, or other infiltrates. "T-lymphocytes" denotes lymphocytes that are phenotypically CD3+, typically detected using an anti-CD3 monoclonal antibody in combination with a suitable labeling technique. The T-lymphocytes of this invention are also generally positive for CD4, CDB, or both. The term "naive"
immune effector cells refers to immune effector cells that have not encountered antigen and is intended to by synonymous with unprimed and virgin. "Educated"
refers to immune effector cells that have interacted with an antigen such that they differentiate into an antigen-specific cell.
An "effective amount" is an amount sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, applications or dosages. The proteins, peptides and polynucleotides of the present invention may be administered or applied transdermally, orally, subcutaneously, intramuscularly, intravenously, intradermally or parenterally. For purposes of this invention, an effective amount of the protein, peptide or polynucleotide is that amount which provokes an antigen-specific immune response in the subject.
The terms "polynucleotide" and "nucleic acid molecule" are used interchangeably to refer to polymeric forms of nucleotides of any length. The polynucleotides may contain deoxyribonucleotides, ribonucleotides, and/or their analogs. Nucleotides may have any three-dimensional structure, and may perform any function, known or unknown. The term "polynucleotide" includes single-, double-stranded and triple helical molecules.
"Oligonucleotide" refers to polynucleotides of between about 5 and about 100 nucleotides of single- or double-stranded DNA. Oligonucleotides are also known as oligomers or oligos and may be isolated from genes, or chemically synthesized by methods known in the art. A "primer" refers to an oligonucleotide, usually single-stranded, that provides a 3'-hydroxyl end for the initiation of enzyme-mediated nucleic acid synthesis.
The following are non-limiting embodiments of polynucleotides: a gene or gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A nucleic acid molecule may also comprise modified nucleic acid molecules, such as methylated nucleic acid molecules and nucleic acid molecule analogs. Analogs of purines and pyrimidines are known in the art, and include, but are not limited to, aziridinycytosine, 4-acetylcytosine, S-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethyl-aminomethyluracil, inosine, N6-isopentenyladenine, 1-methyladenine, 1-methylpseudouracil, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, pseudouracil, 5-pentylnyluracil and 2,6-diaminopurine. The use of uracil as a substitute for thymine in a deoxyribonucleic acid is also considered an analogous form of pyrimidine. By way of example only and not to limit this invention, the polynucleotides encode a peptide, a ribozyme or an antisense sequence.
The terms "protein," "oligopeptide," "polypeptide" and "peptide" are used interchangeably to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the def nition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modification known in the art.
A "subject" is a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, marines, simians, humans, farm animals, sport animals, and pets. The term "predetermined site" refers to the region of the subject into which it is intended that the methods described herein will be practices. Preferably, the predetermined site is a region that is naturally rich in antigen presenting cells such as skin.
By "priming" is meant any treatment or preparation causing a desired result. For purposes of the this invention, priming a site means preparing that site for administration of transgene by first recruiting antigen presenting cells to that site.
The terms "antigen presentation cells" or "APCs" includes both intact, whole cells as well as other molecules which are capable of inducing the presentation of one or more antigens, preferably with class I MHC molecules.
Examples of suitable APCs are discussed in detail below and include, but are not limited to, whole cells such as macrophages, dendritic cells and B cells.
Dendritic cells (DCs) are potent antigen-presenting cells (APCs). It has been shown that DCs provide all the signals required for T cell activation and proliferation. These signals can be categorized into two types. The first type, which gives specificity to the immune response, is mediated through interaction between the T-cell receptor/CD3 ("TCR/CD3") complex and an antigenic peptide presented by a major histocompatibility complex ("MHC") class I or II protein on the surface of APCs. This interaction is necessary, but not sufficient, for T
cell activation to occur. In fact, without the second type of signal, the first type of signals can result in T cell anergy. The second type of signal, called a costimulatory signal, is neither antigen-specific nor MHC-restricted, and can lead to a full proliferation response of T cells and induction of T cell effector functions in the presence of the first type of signals.
DCs are minor constituents of various immune organs such as spleen, thymus, lymph node, epidermis, and peripheral blood. For instance, DCs represent merely about 1 % of crude spleen (Steinman et al. ( 1979) J. Exp.
Med.
149:1) or epidermal cell suspensions (Schuler et al. (1985) J. Exp. Med.
161:526;
and Romani et al. (1989) J. Invest. Dermatol. 93:600), and 0.1-1% of mononuclear cells in peripheral blood (Freudenthal et al. (1990) Proc. Natl. Acad. Sci.
USA
87:7698). Methods for generating dendritic cells from peripheral blood or bone marrow progenitors have been described (Inaba et al. (1992) J. Exp. Med.
175:1157; Inaba et al. (1992) J. Exp. Med. 176:1693-1702; Romani et al. (1994) J. Exp. Med. 180:83-93; Sallusto et al. (1994) J. Exp. Med.179:1109-1118;
Bender et al. (1996) J. Imm. Methods 196:121-135; and Rornani et al. (1996) J.
Imm. Methods 196:137-151).
"Co-stimulatory molecules" are molecules involved in the interaction between receptor-ligand pairs expressed on the surface of antigen presenting cells and T cells. "Co-stimulatory activity" was originally defined as an activity provided by bone-marrow-derived accessory cells such as macrophages and dendritic cells, the so called "professional" APCs. Several molecules have been shown to enhance co-stimulatory activity. These are heat stable antigen (HSA) (Liu Y. et al. (1992) J. Exp. Med.175:437), chondroitin sulfate-modified MHC
invariant chain (Ii-CS) (Naujokas M.F. et al. (1993) Cell 74:257), intracellular adhesion molecule 1 (ICAM-1) (Van Seventer G.A. (1990) J. ImmunoL
144:4579), B7-1 and B7-2/B70 (Schwartz R.H. (1992) Cell 71:1065) and B7's counter-receptor CD28 or CTLA-4 on T cells (Freeman et al. (1993) Science 262:909; Young et al. (1992) J. Clin. Invest 90: 229; and Nabavi et al. (1992) Nature 360:266). Other important co-stimulatory molecules are CD40, CD54, ~CD80, CD86. As used herein, the term "co-stimulatory molecule" encompasses any single molecule or combination of molecules which, when acting together with a peptide/MHC complex bound by a TCR on the surface of a T cell, provides a co-stimulatory effect which achieves activation of the T cell that binds the peptide. The term thus encompasses B7, or other co-stimulatory molecules) on an antigen-presenting matrix such as an APC, fragments thereof (alone, complexed with another molecule(s), or as part of a fusion protein) which, together with peptide/MHC complex, binds to a cognate ligand and results in activation of the T cell when the TCR on the surface of the T cell specifically binds the peptide. Co-stimulatory molecules are commercially available from a variety of sources, including, for example, Beckman Coulter. It is intended, although not always explicitly stated, that molecules having similar biological activity as wild-type or purified co-stimulatory molecules (e.g., recombinantly produced or muteins thereof) are intended to be used within the spirit and scope of the invention.
The terms "antigen presenting cell recruitment or proliferation factors" or "APC recruitment or proliferation factors" includes both intact, whole cells as well as other molecules which are capable of recruiting antigen presenting cells.
APC recruitment or proliferation factors include "proinflammatory agents,"
"chemotactic agents," "growth factors" and "mitogenic agents." Numerous mediators of dendritic cell migration and proliferation have been described in both in vitro and in vivo models. Examples of suitable APC factors include molecules such as interleukin 4 (IL4), granulocyte macrophage colony stimulating factor (GM-CSF), Sepragel and macrophage inflammatory protein 3 alpha (MIP3a).
Schering-Plough, Genzyme, Immunex. Other APC recruitment or proliferation factors include cytokines such as IL-2, stem cell factor (SCF), IL-3, IL-6, IL-12, G-CSF, GM-CSF, IL-la, IL-11, MIP-la, LIF, c-kit ligand, TPO, and flt3 ligand.
Cytokines are commercially available from several vendors such as, for example, Genentech (South San Francisco, CA), Amgen (Thousand Oaks, CA) and Immunex (Seattle, WA). It is intended, although not always explicitly stated, that t molecules having similar biological activity as wild-type or purified APC
recruitment or proliferation factors (e.g., recombinantly produced) are intended to be used within the spirit and scope of the invention.
In vitro, dendritic cell chemotaxis is induced by macrophage-derived chemokine (MDC) (Godiska et al. ( 1997) J. Exp. Med. 185:1595:1604), formyl peptides, CSa, and chemokines such as monocyte chemotactic protein (MCP)-3 and RANTES (Morelli et al. (1996) Immunology 89:126-134; Sozzani et al.
(1995) J. Immunol. 155:3292-3295). However, human dendritic cell chemotaxis is not induced by IL-8, IL-10, MCP-1, and MCP-2 in vitro (Sozzani et al.
(1995) supra). The proliferation and maturation of cultured dendritic cells is promoted by granulocyte macrophage-colony stimulating factor (GM-CSF) GM-CSF (Caux et al. (1992) Nature 360:258-261; Witmer-Pack et al. (1987) J. Exp. Med.
166:1484-1498). In vivo, the number of Langerhans cells, a type of dendritic cell, has been increased in response to GM-CSF in the skin (Kaplan et al. (1992) J.
1 S Exp. Med.175:1717); O'Sullivan et al. (1997) Exp. Dermatol. 6:236-242) and in the lungs (Tazi et al. (1993) J. Clin. Invest. 91:566-576). In addition, Langerhans cell recruitment or proliferation to the skin has been induced using splenopentin (a pentapeptide hormone) (Gruner et al. (1990) Arch. Dermatol. Res. 281:526-529).
Recombinant marine GM-CSF (mGM-CSF) (Genzyme Corporation, Cambridge, MA) is a glycosylated polypeptide (23-29kD) (Burgess et al. (1977) J.
Biol. Chem. 252:1998-2003) of 142 amino acids (Gough et al. (1985) Nature 309:763-767). Human GM-CSF (hGM-CSF) is a glycoprotein of 22kD (Gasson et al. (1984) Science 226:1339-1342) of 144 amino acids (along et al. {1985) Cancer Cells 3:235-242). The homology between marine and human GM-CSF is 60% and there is no species cross reactivity. Recombinant prolactin (PRL) (Genzyme Corporation, Cambridge, MA) is a protein with a molecular weight of about 25 kD consisting of 205 amino acids. Sepragel (Genzyme Corporation, Cambridge, MA) is a cross-linked hyaluronic acid gel. Recombinant adenoviral vectors expressing mGM-CSF (Ad2/cmvGMCSFF9ix) and human prolactin (Ad2/EV/PRL) were made at Genzyme (Framingham, MA).
A "gene delivery vehicle" is defined as any molecule that can carry inserted polynucleotides into a host cell. A "transgene" is the term given to the polynucleotide carried by the gene delivery vehicle. The term "transduction"
refers to the transfer of polynucleotides into a host cell. Examples of gene delivery vehicles are liposomes, viruses, such as baculovirus and retrovirus, bacteriophage, cosmid, plasmid, fungal vectors and other recombination vehicles typically used in the art which have been described for expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple protein expression.
A "viral vector" is defined as a recombinantly produced virus or viral particle that comprises a polynucleotide to be delivered into a host cell, either in vivo, ex vivo or in vitro. Examples of viral vectors include retroviral vectors, adenovirus vectors, adeno-associated virus vectors and the like.
In aspects where gene transfer is mediated by a retroviral vector, a vector construct refers to the polynucleotide comprising the retroviral genome or part thereof, and a therapeutic gene. As used herein, "retroviral mediated gene transfer" or "retroviral transduction" carnes the same meaning and refers to the process by which a gene or nucleic acid sequences are stably transferred into the host cell by virtue of the virus entering the cell and integrating its genome into the host cell genome. The virus can enter the host cell via its normal mechanism of infection or be modified such that it binds to a different host cell surface receptor or ligand to enter the cell. Retroviruses carry their genetic information in the form of RNA; however, once the virus infects a cell, the RNA is reverse-transcribed into the DNA form which integrates into the genomic DNA of the infected cell.
The integrated DNA form is called a provints.
In aspects where gene transfer is mediated by a DNA viral vector, such as a adenovirus (Ad) or adeno-associated virus (AAA, a vector construct refers to the polynucleotide comprising the viral genome or part thereof, and a therapeutic gene. Adenoviruses (Ads) are a relatively well characterized, homogenous group of viruses, including over 50 serotypes. (see, e.g., WO 95/27071 ) Ads are easy to grow and do not require integration into the host cell genome. Recombinant Ad-derived vectors, particularly those that reduce the potential for recombination and generation of wild-type virus, have also been constructed. (see, e.g. WO
95/00655; WO 95/11984). Wild-type AAV has high infectivity and specificity integrating into the host cells genome. (Hermonat and Muzyczka (1984) Proc.
Natl. Acad. Sci. USA 81:6466-6470; Lebkowski et al. (1988} Mol. Cell. Biol.
8:3988-3996).
Vectors that contain both a promoter and a cloning site into which a polynucleotide can be operatively linked are well known in the art. Such vectors are capable of transcribing RNA in vitro or in vivo, and are commercially available from sources such as Stratagene (La Jolla, CA) and Promega Biotech (Madison, WI). In order to optimize expression and/or in vitro transcription, it may be necessary to remove, add or alter 5' and/or 3' untranslated portions of the clones to eliminate extra, potential inappropriate alternative translation initiation codons or other sequences that may interfere with or reduce expression, either at the level of transcription or translation. Alternatively, consensus ribosome binding sites can be inserted immediately S' of the start codon to enhance expression.
Among these are several non-viral vectors, including DNA/liposome complexes, and targeted viral protein DNA complexes. To enhance delivery to a cell, the nucleic acid or proteins of this invention can be conjugated to antibodies or binding fragments thereof which bind cell surface antigens, e.g., TCR, CD3 or CD4. Liposomes that also comprise a targeting antibody or fragment thereof can be used in the methods of this invention. This invention also provides the targeting complexes for use in the methods disclosed herein.
Polynucleotides are inserted into vector genomes using methods well known in the art. For example, insert and vector DNA can be contacted, under suitable conditions, with a restriction enzyme to create complementary ends on each molecule that can pair with each other and be joined together with a ligase.
Alternatively, synthetic nucleic acid linkers can be ligated to the termini of restricted polynucleotide. These synthetic linkers contain nucleic acid sequences that correspond to a particular restriction site in the vector DNA.
Additionally, an oligonucleotide containing a termination colon and an appropriate restriction site can be ligated for insertion into a vector containing, for example, some or all of the following: a selectable marker gene, such as the neomycin gene for selection of stable or transient transfectants in mammalian cells; enhancer/promoter sequences from the immediate early gene of human CMV for high levels of transcription; transcription termination and RNA processing signals from SV40 for mRNA stability; SV40 polyoma origins of replication and ColEl for proper episomal replication; versatile multiple cloning sites; and T7 and SP6 RNA
promoters for in vitro transcription of sense and antisense RNA. Other means are well known and available in the art.
As used herein, "expression" refers to the process by which polynucleotides are transcribed into mRNA and translated into peptides, polypeptides, or proteins. If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA, if an appropriate eukaryotic host is selected. Regulatory elements required for expression include promoter sequences to bind RNA polymerise and transcription initiation sequences for ribosome binding. For example, a bacterial expression vector includes a promoter such as the lac promoter and for transcription initiation the Shine-Dalgarno sequence and the start colon AUG (Sambrook et al. (1989) supra ). Similarly, an eukaryotic expression vector includes a heterologous or homologous promoter for RNA polymerise II, a downstream polyadenylation signal, the start colon AUG, and a termination colon for detachment of the ribosome. Such vectors can be obtained commercially or assembled by the sequences described in methods well known in the art, for example, the methods described below for constructing vectors in general.
"Host cell" is intended to include any individual cell or cell culture which can be or have been recipients for vectors or the incorporation of exogenous nucleic acid molecules, polynucleotides and/or proteins. It also is intended to include progeny of a single cell, and the progeny may not necessarily be completely identical (in morphology or in genomic or total DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation.
The cells may be prokaryotic or eukaryotic, and include but are not limited to bacterial cells, yeast cells, animal cells, and mammalian cells, e.g., marine, rat, simian or human.
An "antibody" is an immunoglobulin molecule capable of binding an antigen. As used herein, the term encompasses not only intact immunoglobulin molecules, but also anti-idiotypic antibodies, mutants, fragments, fusion proteins, humanized proteins and modifications of the immunoglobulin molecule that comprise an antigen recognition site of the required specificity.
A "composition" is intended to mean a combination of active agent and another compound or composition, inert (for example, a detectable agent or label) or active, such as an adjuvant.
A "pharmaceutical composition" is intended to include the combination of an active agent with a carrier, inert or active, making the composition suitable for diagnostic or therapeutic use in vitro, in vivo or ex vivo.
As used herein, the term "pharmaceutically acceptable carnet"
encompasses any of the standard pharmaceutical carnets, such as a phosphate buffered saline solution, water, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carnets, stabilizers and adjuvants, see Martin, xi;MiNGTON'S PHAi~t. SCI., 15th Ed. (Mack Publ. Co., Easton (1975)).
As used herein, the term "comprising" is intended to mean that the compositions and methods include the recited elements, but not excluding others.
"Consisting essentially of when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination.
Thus, a composition consisting essentially of the elements as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like. "Consisting of shall mean excluding more than trace elements of other ingredients and substantial method steps for administering the compositions of this invention. Embodiments defined by each of these transition terms are within the scope of this invention.
This invention provides a method to enhance the recruitment or increase the number of APCs to a predetermined site or location in a subject by administering to the subject an effective amount of an APC recruitment or proliferation factor and under conditions which favor the recruitment or increase in the number of APC to the site of administration. In one aspect, the factor is formulated for slow release (i.e., in a sponge or liposome) so as to create a sustained localized concentration of the APC recruitment or proliferation factor.
The recruitment or proliferation factor is, in some embodiments, GM-CSF or Supragel. The recruitment or proliferation factor also includes, but is not limited to, biological equivalents of these protein such as amino acid sequences having conservative amino acid substitutions and fusion proteins. This may include yet unidentified proteins which may be assayed in the animal model presented below.
The biological activity of an equivalent protein can be assayed by using the animal model detailed below.
The recruitment or proliferation factor of this invention also can be administered as a polynucleotide or gene coding for the factor. These polynucleotides can be delivered using conventional gene therapy delivery vehicles, vectors and methods as provided below. Either of these means of delivering the recruitment or proliferation factor of this invention can be further modified by the co-administration of a growth factor, a cytokine, a co-stimulatory molecule or a mitogenic molecule, prior to, subsequently to or concurrently with the recruitment or proliferation factor. Alternatively, a host cell can be transduced with genes) encoding these molecules which is then administered to the subject.
In one aspect of the invention, the host cell containing the gene{s) coding for the ctyokine and/or co-stimulatory molecule is a professional antigen-presenting cell such as a dendritic cell which includes, but is not limited to, a pulsed dendritic cell, a dendritic cell hybrid or an antigen-presenting foster cell.
Presentation of the antigens such as tumor associated antigens by the APCs elicits a strong immune response resulting in destruction of tumor cells by antigen-specific immune effector cells such as cytotoxic T lymphocyte cells (CTLs). Thus, in one aspect, this is achieved by recruiting antigen presenting cells to a predetermined site in a subject, by administering an effective amount of an APC recruitment or proliferation factor. The induction of the CTL response is one method to assay for a positive response to the therapy and a means to confirm the biological activity of new factors useful in the methods of this invention. The presence of a large number of T-cells in a tumor has been correlated with a prognostically favorable outcome in some cases (Whiteside and Parmiani (1994) Cancer Immunol. Immunother. 39:15-21 ). It has been shown that implantation of polyurethane sponges containing irradiated tumor cells can efficiently trap anti-tumor CTLs (4-times greater than lymph fluid, 50-times greater than spleen or peripheral blood). Woolley et al. (1995) Immmunology 84:55-63. Following activation with T-cell cytokines in the presence of their appropriately presented recognition antigen, TILs proliferate in culture and acquire potent anti-tumor cytolytic properties. Weidmann et al. (1994) Cancer Immunol. Immunother. 39:1-14. Assays to determine T cell response are well known in the art and any method that will compare T cell number prior to, and subsequent to therapy can be utilized. In addition, the induction of co-stimulatory molecules by the polynucleotide could also stimulate anergic or low affinity self reactive CTL
clones. Methods to assay for CTL clones include: standard s'Cr release assay as described in Kawakami et al. (1988) J. Exp. Med. 168:2183-91. Briefly, cytotoxic T cells are added to target cells previously loaded with s'Cr and one measures the release of 5'Cr from the lysed target cells. Cytokine release assay can be used as described in Kawakami et al. (1994) Proc. Natl. Acad. Sci. USA 91:3515-19.
Briefly, cytotoxic T cells are added to target cells and one measures the amount of IFNY released by ELISA. To measure the relative proportion of immune effector cells within a mixed population that recognize a particular target, the Enzyme-LInked immunoSPOT (ELISPOT) assay is employed as described in Czerkinsky et al. ( 1988) J. Immunol. Methods 110:29-36. Briefly, 96 well nitrocellulose-bottomed plates are coated with an anti-cytokine antibody, generally anti-interferon-y. Target cells and immune effector cells such as cytotoxic T cells (CTLs) are added to wells. Cytokine released from the CTLs is captured by the anti-interferon-y antibody and quantitated using a standard ELISA format.
In another aspect, the present invention provides a method to enhance presentation of an antigen into antigen presenting cells (APCs) in vivo, by priming a predetermined site in a subject with an effective amount of an APC
recruitment or proliferation factor, and administering an effective amount of the antigen to the site. The antigen is administered as a protein, a recombinant protein, or a peptide.
This invention further provides a method to augment transduction of transgenes into APCs in vivo, by priming a predetermined site in a subject with an effective amount of an APC recruitment or proliferation factor and administering an effective amount of the transgene, which may be a tumor associated antigen.
The antigen of this vaccine may be an altered antigen or heterologous (i.e., allogeneic or a homolog from a isolated species, e.g., a marine antigen administered to a human patient). It may be a previously characterized tumor-associated antigens such as gp100 (Kawakami et al. (1997) Intern. Rev. Immunol.14:173-192);
MUC-1 (Henderson et al. (1996) Cancer Res. 56:3763-3770); MART-1 (Kawakami et al. (1994) Proc. Natl. Acad. Sci. USA 91:3515-3519; Kawalcami et al. (1997) Intern. Rev. Immunol.14:173-192; and Ribas et al. (1997) Cancer Res.
57:2865-2869); HER-2/neu (U.S. Patent No. 5,550,214), MAGE
(PCT/US92/04354); HPV16, 18E6 and E7 (Ressing et al. (1996) Cancer Res.
56(1):582-588; Rstifo (1996) Curr. Op. Immunol. 8:658-663; Stern (1996) Adv.
Cancer Res. 69:175-211; Tindle et al. (1995) Clin. Exp. Immunol. 101:265-271;
and van Driel et al. (1996) Annals of Medicine 28:471-477); CEA (LT.S. Patent No. 5,274,087); PSA (Lundwall A. (1989) Biochem. Biophys. Research Comm.
161:1151-59); prostate membrane specific antigen (PSMA) (Israeli et al. (1993) Cancer Research 53:227-30); tyrosinase (U.S. Patent Nos. 5,530,096 and 4,898,814; Brichard et al. (1993) J. Exp. Med.178:489-49); tyrosinase related proteins 1 or 2 (TRP-1 and TRP-2); NY-ESO-1 (Chen et al. (1997) Proc. Natl.
Acad. Sci. USA 94:1914-18); or the GA733 antigen (U.S. Patent No. 5,185,254).
The coding and amino acid sequences of these antigens are available in the art.
For example, human and marine MUC 1 coding sequences are provided under Genbank Accession No. M35093 and M64928.
Biologically equivalent proteins of known antigens also are useful in the methods described herein. These proteins are encoded by polynucleotides that hybridize under stringent conditions to the sequences disclosed in the references described above or known in the art. Alternatively, the proteins are encoded by polynucleotides that are at least 80%, or more preferably, at least 90% or most preferably, at least 95%, identical to the disclosed sequences using as determined using sequence alignment programs and default parameters.
"Hybridization" refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding between the bases of the nucleotide residues. The hydrogen bonding may occur by Watson-Crick base pairing, Hoogstein binding, or in any other sequence-specific manner. The complex may comprise two strands forming a duplex structure, three or more strands forming a mufti-stranded complex, a single self hybridizing strand, or any combination of these. A hybridization reaction may constitute a step in a more extensive process, such as the initiation of a PCR reaction, or the enzymatic cleavage of a polynucleotide by a ribozyme.
Examples of stringent hybridization conditions include: incubation temperatures of about 25°C to about 37°C; hybridization buffer concentrations of about 6 X SSC to about 10 X SSC; formamide concentrations of about 0% to about 25%; and wash solutions of about 6 X SSC. Examples of moderate hybridization conditions include: incubation temperatures of about 40°C
to about 50°C; buffer concentrations of about 9 X SSC to about 2 X SSC;
formamide concentrations of about 30% to about 50%; and wash solutions of about 5 X SSC
WOl9/47179 PCT/US99/06071 to about 2 X SSC. Examples of high stringency conditions include: incubation temperatures of about 55°C to about 68°C; buffer concentrations of about 1 X
SSC to about 0.1 X SSC; fortnamide concentrations of about 55% to about 75%;
and wash solutions of about 1 X SSC, 0.1 X SSC, or deionized water. In general, hybridization incubation times are from S minutes to 24 hours, with 1, 2, or more washing steps, and wash incubation times are about 1, 2, or 15 minutes. SSC is 0.1 S M NaCI and I 5 mM citrate buffer. It is understood that equivalents of SSC
using other buffer systems can be employed.
A polynucleotide or polynucleotide region (or a polypeptide or polypeptide region} has a certain percentage (for example, 80%, 85%, 90%, or 95%) of "sequence identity" to another sequence means that, when aligned, that percentage of bases (or amino acids) are the same in comparing the two sequences. This alignment and the percent homology or sequence identity can be determined using software programs known in the art, for example those described in CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (F.M. Ausubel et al., eds., 1987) Supplement 30, section 7.7.18, Table 7.7.1. Preferably, default parameters are used for alignment. A preferred alignment program is BLAST, using default parameters. In particular, preferred programs are BLASTN and BLASTP, using the following default parameters: Genetic code = standard;
filter = none; strand = both; cutoff= 60; expect =10; Matrix = BLOSUM62;
Descriptions = 50 sequences; sort by = HIGH SCORE; Databases = non-redundant, GenBank + EMBL + DDBJ + PDB + GenBank CDS translations +
SwissProtein + SPupdate + PIR. Details of these programs can be found at the following Internet address: http://www.ncbi.nlm.nih.gov/cgi-bin/BLAST.
It also may be a yet undetermined antigen identified by the methods described herein or well known to those of skill in the art.
The antigen can be administered as a protein, a recombinant protein, a peptide, or, alternatively, a polynucleotide in a gene delivery vehicle.
Furthermore, the invention provides a method for cloning the cDNA and genomic DNA encoding novel recruitment or proliferation factors identified by this invention, by generating degenerate oligonucleotides probes or primers based on the sequence of the epitope. Compositions comprising the nucleic acid and a carrier, such as a pharmaceutically acceptable carrier, a solid support or a detectable label, are further provided by this method as well as methods for S detecting the sequences in a sample using methods such as Northern analysis, Southern analysis and PCR.
Further provided by this invention are therapeutic and diagnostic oligopeptide sequences determined according to the foregoing methods.
Compositions comprising the oligopeptide sequence and a carrier, such as a pharmaceutically acceptable Garner, a solid support or a detectable label, are further provided by this method as well as methods for detecting the oligopeptide sequence in a sample using methods such as Western analysis and ELISA.
Harlow and Lane (1988), supra.
Materials and Methods Identification of Tumor Associated Antigens Any conventional method, e.g., subtractive library, comparative Northern and/or Western blot analysis of normal and tumor cells, Serial Analysis of Gene Expression (LT.S. Patent No. 5,695,937) and Solid PHase Epitope REcovery ("SPHERE," described in PCT WO 97/35035), can be used to identify putative antigens for use in the subject invention.
Expression cloning also can be used. This methodology, as described in Kawakami et al. (1994) Proc. Natl. Acad. Sci. USA 91:3515-19, can be used to identify a novel tumor-associated antigen. Briefly, a library of cDNAs corresponding to mRNAs derived from tumor cells is cloned into an expression vector and introduced into target cells which are subsequently incubated with cytotoxic T cells. One identifies pools of cDNAs that are able to stimulate the CTL and through a process of sequential dilution and re-testing of less complex pools of cDNAs one is able to derive unique cDNA sequences that are able to stimulate the CTL and thus encode the cognate tumor antigen.
SAGE analysis involves identifying nucleotide sequences expressed in the antigen-expressing cells. Briefly, SAGE analysis begins with providing complementary deoxyribonucleic acid (cDNA) from ( 1 ) the antigen-expressing population and (2) cells not expressing that antigen. Both cDNAs can be linked to primer sites. Sequence tags are then created, for example, using the appropriate primers to amplify the DNA. By measuring the differences in these tags between the two cell types, sequences which are aberrantly expressed in the antigen-expressing cell population can be identified.
Alternatively, muteins of the antigen as well as allogeneic and antigens from a different species, of previously characterized antigens are useful in the subject invention. MART1 and gp100 are melanocyte differentiation antigens specifically recognized by HLA-A2 restricted tumor-infiltrating lymphocytes (TILs) derived from patients with melanoma, and appear to be involved in tumor regression (Kawakami, Y. et al. (1994) Proc. Natl. Acad. Sci. USA 91:6458-62;
Kawakami, Y. et al. (1994) Proc. Natl. Acad. Sci. USA 91:91:3515-9). Recently, the mouse homolog of human MART-1 has been isolated. The full-length open reading frame of the mouse MART1 consists of 342 bp, encoding a protein of 113 amino acid residues with a predicted molecular weight of ~13 kDa. Alignment of human and marine MART1 amino acid sequences showed 68.6% identity.
The marine homologue of gp100 has also been identified. The open reading frame consists of 1,878 bp, predicting a protein of 626 amino acid residues which exhibits 75.5% identity to human gp100.
SPHERE, described in PCT WO 97/35035, is a method that will identify wild-type or native antigens as well as provide altered antigens. SPHERE is an empirical screening method for the identification of MHC Class I-restricted CTL
epitopes that utilizes peptide libraries synthesized on a solid support (e.g., plastic beads) where each bead contains approximately 200 picomoles of a unique peptide that can be released in a controlled manner. The synthetic peptide library is tailored to a particular HLA restriction by fixing anchor residues that confer high-affinity binding to a particular HLA allele (e.g., HLA-A2) but contain a variable TCR epitope repertoire by randomizing the remaining positions.
Roughly speaking, 50 96-well plates with 10,000 beads per well will accommodate a library with a complexity of approximately 5 X 10'. In order to minimize both the number of CTL cells required per screen and the amount of manual manipulations, the eluted peptides can be further pooled to yield wells with any desired complexity. Based on experiments with soluble libraries, it should be possible to screen 10' peptides in 96-well plates (10,000 peptides per well) with as few as 2 X 1 O6 CTL cells. After cleaving a percentage of the peptides from the beads ami incubating them with 5'Cr-labeled APCs (e.g., T2 cells) and the CTL line(s), peptide pools containing reactive species can be determined by measuring StCr-release according to standard methods known in the art. Alternatively, cytokine production (e.g., interferon-Y) or proliferation (e.g., incorporation of 3H-thymidine) assays may be used. After identifying reactive 10,000-peptide mixtures, the beads corresponding to those mixtures are separated into smaller pools and distributed to new 96-well plates (e.g., 100 beads per well).
An additional percentage of peptide is released from each pool and reassayed for activity by one of the methods listed above. Upon identification of reactive peptide pools, the beads corresponding those peptide mixtures are redistributed at 1 bead per well of a new 96-well plate. Once again, an additional percentage of peptide is released and assayed for reactivity in order to isolate the single beads containing the reactive library peptides. The sequence of the peptides on individual beads can be determined by sequencing residual peptide bound to the beads by, for example, N-terminal Edman degradation or other analytical techniques known to those of skill in the art.
In vitro confirmation of the immunogenicity of a putative antigen of this invention can be confirmed using the method described below, which assays for the production of CTLs.
Isolation, Culturing and Expansion of APCs, Including Dendritic Cells Bender et al. (1996) J. Immunol. Meth. 196:121-135 describes a method for generating sizable numbers of mature dendritic cells from nonproliferating r progenitors in human blood. The procedure requires 1 % human plasma in the place of 10% fetal calf serum and involves two steps. The first step or "priming"
phase is a 6-7 day culture of T cell depleted mononuclear cells in medium supplemented with GM-CSF and IL-4. The second step or "differentiation" phase requires the exposure to macrophage conditioned medium.
Romani et al. (1996) J. Immunol. Methods 196:137-151 describes a method to generate human dendritic cells from hematopoietic precursor cells in peripheral blood. A 3 day maturation culture is added to the initial 6-7 day culture in the presence of GM-CSF and IL-4. Human plasma, rather than fetal calf serum and media approved for clinical use are optimal, additional conditions for use in this method.
The following describe additional methods. In one aspect, a large numbers of precommitted APCs already circulating in the bload are isolated. Previous techniques for isolating committed APCs from human peripheral blood have involved combinations of physical procedures such as metrizamide gradients and adherence/nonadherence steps (Freudenthal et al. (1990) PNAS USA 87:7698-7702); Percoll gradient separations (Mehta-Damani et al. ( 1994) J. Immunol.
153:996-1003); and fluorescence activated cell sorting techniques (Thomas R.
et al. (1993) J. Immunol. 151:6840-52).
The APC can be precommitted or mature dendritic cells, which can be isolated from the white blood cell fraction of a mammal, such as a marine, simian or a human (See, e.g., WO 96/23060). The white blood cell fraction can be from the peripheral blood of the mammal. This method includes the following steps:
(a) providing a white blood cell fraction obtained from a mammalian source by methods known in the art such as leukophoresis; (b) separating the white blood cell fraction of step (a) into four or more subfractions by countercurrent centrifugal elutriation; (c) stimulating conversion of monocytes in one or more fractions from step (b) to dendritic cells by contacting the cells with calcium ionophore; (d) identifying the dendritic cell-enriched fraction from step (c);
and (e) collecting the enriched fraction of step (d), preferably at about 4°C. One way to identify the dendritic cell-enriched fraction is by fluorescence-activated cell sorting (FACS). The white blood cell fraction can be treated with calcium ionophore in the presence of other cytokines, such as rhIL-12, rhGM-CSF, or rhIL-4. The cells of the white blood cell fraction can be washed in buffer and suspended in Ca'+/Mg~ free media prior to the separating step. The white blood cell fraction can be obtained by leukapheresis. The dendritic cells can be identified by the presence of at least one of the following markers: HLA-DR, HLA-DQ, or B7.2, and the simultaneous absence of the following markers: CD3, CD14, CD16, 56, 57, and CD 19, 20. Monoclonal antibodies specific to these cell surface markers are commercially available.
More specifically, the method requires collecting an enriched collection of white cells and platelets from leukapheresis that is then further fractionated by countercurrent centrifugal elutriation (CCE} (Abrahamsen, T.G. et aI. (1991) J.
Clin. Apheresis. 6:48-53). Cell samples are placed in a special elutriation rotor.
The rotor is then spun at a constant speed of, for example, 3000 rpm. Once the rotor has reached the desired speed, pressurized air is used to control the flow rate of cells. Cells in the elutriator are subjected to simultaneous centrifugation and a washout stream of buffer that is constantly increasing in flow rate. This results in fractional cell separations based largely but not exclusively on differences in cell size.
Quality control of APC and more specifically DC collection and confirmation of their successful activation in culture is dependent upon a simultaneous multi-color FACS analysis technique which monitors both monocytes and the dendritic cell subpopulation as well as possible contaminant T
lymphocytes. It is based upon the fact that DCs do not express the following markers: CD3 (T cell); CD14 (monocyte); CD16, 56, 57 (NK/LAK cells); CD19, 20 (B cells). At the same time, DCs do express large quantities of HLA-DR, significant HLA-DQ and B7.2 (but little or no B7. I ) at the time they are circulating in the blood (in addition they express Leu M7 and M9, myeloid markers which are also expressed by monocytes and neutrophils).
When combined with a third color reagent for analysis of dead cells, propridium iodide (PI), it is possible to make positive identification of all cell subpopulations (see Table 1 ):
FACS analysis of fresh peripheral cell subpopulations Color #1 Color #2 Color #3 Cocktail HLA-DR _PI
Live Dendritic Negative Positive Negative cells Live Monocytes Positive Positive Negative Live NeutrophilsNegative Negative Negative Dead Cells Variable Variable Positive Additional markers can be substituted for additional analysis:
Color #1: CD3 alone, CD14 alone, etc.; Leu M7 or Leu M9; anti-Class I, etc.
Color #2: HLA-Dq, B7.1, B7.2, CD25 (IL2r), ICAM, LFA-3, etc.
The goal of FACS analysis at the time of collection is to confirm that the DCs are enriched in the expected fractions, to monitor neutrophil contamination, and to make sure that appropriate markers are expressed. This rapid bulk collection of enriched DCs from human peripheral blood, suitable for clinical applications, is absolutely dependent on the analytic FACS technique described above for quality control. If need be, mature DCs can be immediately separated from monocytes at this point by fluorescent sorting for "cocktail negative"
cells.
It may not be necessary to routinely separate DCs from monocytes because, as will be detailed below, the monocytes themselves are still capable of differentiating into DCs or functional DC-like cells in culture.
Once collected, the DC rich/monocyte APC fractions (usually 150 through 190) can be pooled and cryopreserved for future use, or immediately placed in short term culture.
Alternatively, others have reported that a method for upregulating (activating) dendritic cells and converting monocytes to an activated dendritic cell phenotype. This method involves the addition of calcium ionophore to the culture media convert monocytes into activated dendritic cells. Adding the calcium ionophore A23187, for example, at the beginning of a 24-48 hour culture period resulted in uniform activation and dendritic cell phenotypic conversion of the pooled "monocyte plus DC" fractions: characteristically, the activated population becomes uniformly CD14 (Leu M3) negative, and upregulates HLA-DR, HLA-DQ, ICAM-1, B7.1, and B7.2. Furthermore this activated bulk population functions as well on a small numbers basis as a further purified.
Specific combinations) of cytokines have been used successfully to amplify (or partially substitute) for the activation/conversion achieved with calcium ionophore: these cytokines include but are not limited to rhGM-CSF, rhIL-2, and rhIL-4. Each cytokine when given alone is inadequate for optimal upregulation.
In one embodiment, the APCs and cells expressing one or more antigens are autologous. In another embodiment, the APCs and cells expressing the antigen are allogeneic, i.e., derived from a different subject.
Administration of APC recruitment or proliferation Factors) In one embodiment, an APC-recruitment or proliferation factor is administered to mice by subcutaneous injection. The APC-recruitment or proliferation factors is administered either as a protein or as a gene therapy vector that is capable of expressing the gene for the APC-enhancing factor. The effective amount can be readily determined, for instance by administering subcutaneous injections at different dosages and evaluating the subsequent inflammatory response at different times after administration.
The APC recruitment or proliferation factors useful in the present invention include, but are not limited to, GM-CSF, PRL, Sepragel, Ad2/cmvGMCSFF9ix, and Ad2/EV/PRL. In addition, it may be necessary to complex the protein form of some of the CEFs to a bead for slow-release into the tissue (Meyer et al. (1994) Biochem. Biophys. Res. Common. 199:433-438;
Tanaka et al. (1991) Cancer Res. 51:3710-3714). The slow release of chemotactic factors establishes a concentration gradient that would facilitate dendritic cell migration towards the APC recruitment or proliferation factor.
An in vitro assay to determine the recruitment efficacy of known or novel APC recruitment factors is the chemotactic assay for cultured dendritic cells as described by Godiska et al. (1997) J. Exp. Med. 185:1595-1604; Morelli et al.
(1996) Immunology 89:126-134; and Sozzani et al. (1995) J. Immunol. 155:3292-3295.
The inflammatory response at the site of APC recruitment or proliferation factor administration can be evaluated by any other known method, for example, in histology sections or in samples taken by needle aspiration. Alternatively, enhanced numbers of dendritic cells, Langerhans cells, and other antigen presenting cells can also be evaluated using either immunohistochemistry or FACS analysis (Kaplan et al. (1992), supra and Tazi et al. (1993) J. Clin.
Invest.
91:566-576).
Alternative routes of administration for gene therapy vectors expressing APC recruitment or proliferation factors are also encompassed by the present invention, and are discussed in detail below. By way of example only, topical administration of recombinant adenoviral vectors to debrided skin (Tang et al.
( 1997) Nature 388:729-730) and gene gun delivery of adenoviral or plasmid vectors (Mahvi et al. (1997) Immunol. Cell. Biol. 75:456-460) can be employed.
The subsequent inflammatory response will be evaluated and compared with the response from the subcutaneous administration.
Administration of Tumor-Associated Antigens ('TAA) Tumor-associated antigens (TAA) can be administered as whole molecules or, preferably, using gene delivery vehicles carrying a polynucleotide encoding the TAA. TAAs may also be administered to APC recruitment or proliferation factor-primed subcutaneous sites in the form of peptides or recombinant proteins.
Typically, gene delivery vehicles expressing a TAA will be administered after treatment with the APC recruitment or proliferation factor. In one aspect, the S TAA is administered in a recombinant adenoviral vector or cationic lipid:DNA
vectors by subcutaneous injection. The TAAs include, but are not limited to, Ad2gp 100; GL67:pCF 1 gp 100; Ad2TRP2; and GL67:pCF 1 TRP2.
The successful transfer of the TAA transgene to APCs, such as dendritic cells or Langerhans cells, at the site of vector administration may be evaluated by any suitable method, for example, using a combination of fluorescence in situ hybridization (FISH) (Gussoni et al. (1996) Nature Biotechnol. 14:1012-1016);
fluorescently labeled lipids or plasmid DNA (Bebok et al. (1996) J. Pharmacol.
Exp. Therapeutics 279:1462-1469 and Matsui et al. (1997) J. Biol. Chem.
272:1117-1126); and immunofluorescence. Transfection of these cell types will also be analyzed by measuring the induction of a specific CTL response against the TAAs (Chen et al. (1993) J. Immunol. 151:244-255). Optimization of transfection conditions will include changes in dose and time after APC
recruitment or proliferation factor administration.
Presentation of Antigen to the APC
Peptide fragments from antigens must first be bound to peptide binding receptors ((MHC) class I and class II molecules) that display the antigenic peptides on the surface of the APCs. Palmer E. and Cresswell ( 1998) Annu.
Rev.
Immunol. 16:323 and Germain R.N. (1996) Immunol. Rev. 151:5. T lymphocytes produce an antigen receptor that they use to monitor the surface of APCs for the presence of foreign peptides. The antigen receptors on TH cells recognize antigenic peptides bound to MHC class II molecules whereas the receptors on CTLs react with antigens displayed on class I molecules. For a general review of the methods for presentation of exogenous antigen by APC, see Raychaudhuri and Rock (1998) Nature Biotechnology 16:1025.
For purposes of immunization, antigens can be delivered to antigen-presenting cells as protein/peptide or in the form of polynucleotides encoding the protein/peptide ex vivo or in vivo. The methods described below focus primarily on DCs which are the most potent, preferred APCs.
Several different techniques have been described to produce genetically modified APCs. These include: (1) the introduction into the APCs of polynucleotides that express antigen or fragments thereof; (2) infection of APCs with recombinant vectors to induce endogenous expression of antigen; and (3) introduction of tumor antigen into the DC cytosol using liposomes. (See Boczkowski D. et al. (1996) J. Exp. Med. 184:465; Rouse et al. (1994) J.
Virol.
68:5685; and Nair et al. (1992) J. Exp. Med. 175:609). For the purpose of this invention, any method which allows for the introduction and expression of the heterologous, altered or non-self antigen and presentation by the MHC on the surface of the APC is within the scope of this invention.
Antigen Pulsing Pulsing is accomplished in vitro%x vivo by exposing APCs to antigenic protein or peptide(s). The protein or peptides) are added to APCs at a concentration of 1-10 Nm for approximately 3 hours. Paglia et al. (1996) J.
Exp.
Med. 183:317, has shown that APC incubated with whole protein in vitro were recognized by MHC class I-restricted CTLs, and that immunization of animals with these APCs led to the development of antigen-specific CTLs in vivo.
Protein/peptide antigen can also be delivered to APC in vivo and presented by the APC. Antigen is preferably delivered with adjuvant via the intravenous, subcutaneous, intranasal, intramuscular or intraperitoneal route of delivery.
Grant E.P. and Rock K.L. (1992) J. Immunol. 148:13; Norbury, C. C. et al. (1995) Immunity 3:783; and Reise-Sousa C. and Germain R.N. (1995) J. Exp. Med.
182:841.
Wp 99/47179 PCT/US99/06071 Antigen Painting Another method which can be used is termed "painting". It has been demonstrated that glycosyl-phosphotidylinositol (GPI)-modified proteins possess the ability to reincorporate themselves back into cell membranes after purification. Hirose et al. (1995) Methods Enzymol. 250:582; Medof et al:
(1984) J. Exp. Med. 160:1558; Medof (1996) FASEB J. 10:574; and Huang et al. (1994) Immunity 1:607, have exploited this property in order to create APCs of specific composition for the presentation of antigen to CTLs. Expression vectors for ~i2-microglobulin and the HLA-A2.1 allele were first devised. The proteins were expressed in Schneider S2 Drosophila melanogaster cells, known to support GPI-modification. After purification, the proteins could be incubated together with a purified antigenic peptide which resulted in a trimolecular complex capable of efficiently inserting itself into the membranes of autologous cells. In essence, these protein mixtures were used to "paint" the APC surface, conferring the ability to stimulate a CTL clone that was specific for the antigenic peptide. Cell coating was shown to occur rapidly and to be protein concentration dependent. This method of generating APCs bypasses the need for gene transfer into the APC and permits control of antigenic peptide densities at the cell surfaces.
Foster Antigen Presenting Cells Foster APCs are derived from the human .dell line 174xCEM.T2, referred to as T2, which contains a mutation in its antigen processing pathway that restricts the association of endogenous peptides with cell surface MHC class I molecules (Zweerink et al. (1993} J. Immunol. 150:1763). This is due to a large homozygous deletion in the MHC class II region encompassing the genes TAP1, TAP2, LMP1, and LMP2, which are required for antigen presentation to MHC
class 1-restricted CD8+ CTLs. In effect, only "empty" MHC class I molecules are presented on the surface of these cells. Exogenous peptide added to the culture medium binds to these MHC molecules provided that the peptide contains the allele-specific binding motif. These T2 cells are referred to herein as "foster"
APCs. They can be used in conjunction with this invention to present the heterologous, altered or control antigen.
Transduction of T2 cells with specific recombinant MHC alleles allows for redirection of the MHC restriction profile. Libraries tailored to the recombinant allele will be preferentially presented by them because the anchor residues will prevent efficient binding to the endogenous allele.
High level expression of MHC molecules makes the APC more visible to the CTLs. Expressing the MHC allele of interest in T2 cells using a powerful transcriptional promoter (e.g., the CMV promoter) results in a more reactive APC
(most likely due to a higher concentration of reactive MHC-peptide complexes on the cell surface).
Preparation of Hybrid Cells Utilizing Dendritic Cells Hybrid cells typically retain the phenotypic characteristics of the APCs.
Thus, hybrids made with dendritic cells will express the same MHC class II
proteins and other cell surface markers. Moreover, the hybrids will express those antigens expressed on the cells from which they are derived.
A population of APCs are collected and isolated. Preferably, the ratio of APCs:antigen-expressing cells is between about 1:100 and about 1000:1. For example, in one aspect, the fraction enriched for antigen-expressing cells.is then fused to APCs, preferably dendritic cells. Fusion between the APCs and antigen-expressing cells can be carried out with any suitable method, for example using polyethylene glycol (PEG) or Sendia virus. In a preferred embodiment, the hybrid cells are created using the procedure described by Gong et al.(1997) Nat. Med.
3(5):558-561.
Typically, unfused cells will die off after a few days in culture. Therefore, the fused cells can be separated from the parent cells simply by allowing the culture to grow for several days. In this embodiment, the hybrid cells both survive more and, additionally, are only lightly adherent to tissue culture surfaces.
The parent cells are strongly adherent to the containers. Therefore, after about 5 to 10 days in culture, the hybrid cells can be gently dislodged and transferred to new containers, while the unfused cells remained attached.
Alternatively, it has been shown that fused cells lack functional hypoxanthine-guaninephosphoribosyl transferase ("HGPRT") enzyme and are, therefore, resistant to treatment with the compound HAT. Accordingly, to select these cells HAT can be added to the culture media. However, unlike conventional HAT selection, hybrid cell cultures should not be exposed to the compound for more than 12 days.
Gene Delivery Vehicles In general, introduction of the transgene or polynucleotide encoding the APC recruitment or proliferation factor or antigen is accomplished in vivo, ex vivo or in vitro by introducing a vector containing a polynucieotide or transgene encoding a heterologous or an altered antigen or APC recruitment or proliferation factor. A variety of different gene transfer vectors, including viral as well as non-viral systems can be used. Viral vectors useful in the genetic modifications of this invention include, but are not limited to adenovirus, adeno-associated virus vectors, retroviral vectors and adeno-retroviral chimeric vectors.
Construction of Recombinant Adenoviral Vectors or Adeno-Associated Virus Vectors Adenovirus and adeno-associated virus vectors useful in the genetic modifications of this invention may be produced according to methods already taught in the art. (see, e.g., Karlsson et al. (1986) EMBO 5:2377; Carter (1992) Curr. Op. Biotechnol. 3:533-539; Muzcyzka (1992) Current Top. Microbiol.
Immunol. 158:97-129; GENE TARGETING: A PRACTICAL APPROACH (1992) ed. A.
L. Joyner, Oxford University Press, NY). Several different approaches are feasible. Preferred is the helper-independent replication deficient human adenovirus system.
The recombinant adenoviral vectors based on the human adenovirus 5 (Virology 163:614-617, 1988) are missing essential early genes from the adenoviral genome (usually ElA/E1B), and are therefore unable to replicate unless grown in permissive cell lines that provide the missing gene products in traps. In place of the missing adenoviral genomic sequences, a transgene of interest can be cloned and expressed in cells infected with the replication deficient adenovirus. Although adenovirus-based gene transfer does not result in integration of the transgene into the host genome (less than 0.1 % adenovirus-mediated transfections result in transgene incorporation into host DNA), and therefore is not stable, adenoviral vectors can be propagated in high titer and transfect non-replicating cells. Human 293 cells, which are human embryonic kidney cells transformed with adenovirus E 1 A/E 1 B genes, typify useful permissive cell lines and are commercially available from the ATCC. However, other cell lines which allow replication-deficient adenoviral vectors to propagate therein can be used, including HeLa cells.
Additional references describing adenovirus vectors and other viral vectors which could be used in the methods of the present invention include the following: Horwitz M.S. Adenoviridae and Their Replication, in Fields B. et al.
(eds.) VIROLOGY, Vol. 2, Raven Press New York, pp. 1679-1721,1990);
Graham, F. et al., pp. 109-128 in METHODS IN MOLECULAR BIOLOGY, Vol. 7: GENE
TRANSFER AND EXPRESSION PROTOCOLS, Murray, E. (ed.), Humana Press, Clifton, N.J. (1991); Miller, N. et al. (1995) FASEB Journal 9:190-199 Schreier, H.
(1994) Pharmaceutics Acta Helvetiae 68:145-159; Schneider and French (1993) Circulation 88:1937-1942; Curiel, D.T. et al. (1992) Human Gene Therapy 3: 147-154;
Graham, F.L. et al., WO 95/00655; Falck-Pedersen, E.S. WO 95/16772; Denefle, P.
et al. WO 95/23867; Haddada, H. et al. WO 94/26914; Perricaudet, M. et al.
WO 95/02697; and Zhang, W. et al. WO 95/25071. A variety of adenovirus plasmids are also available from commercial sources, including, e.g., Microbix Biosystems of Toronto, Ontario, Canada (see, e.g., Microbix Product Information Sheet: Plasmids for Adenovirus Vector Construction, 1996). See also, the papers by Vile et al. (1997) Nature Biotech. 15:840-841; Feng et al. (1997) Nature Biotech. 15:866-870, describing the construction and use of adeno-retroviral chimeric vectors that can be employed for genetic modifications.
Additional references describing AAV vectors which could be used in the methods of the present invention include the following: Carter B., HANDBOOK of PARVOVIRUSES, Vol. I, pp. 169-228, 1990; Berns, VIROLOGY, pp. 1743-1764 (Raven Press 1990); Carter, B. (1992) Curr. Opin. Biotechnol. 3:533-539;
Muzyczka N. (1992) Current Topics in Micro. and Immunol. 158:92-129;
Flotte, T.R. et al. (1992) Am. J. Respir. Cell Mol. Biol. 7:349-356;
Chatterjee et al. (1995) Ann. NY Acad. Sci. 770:79-90; Flotte, T.R. et al. WO 95/13365;
Trempe, J.P. et al. WO 95/13392; Kotin, R. (1994) Human Gene Therapy, 5:793-801; Flotte, T.R. et al. (1995) Gene Therapy 2:357-362; Allen, J.M.
WO 96/17947; and Du et al. (1996) Gene Therapy 3:254-261.
Construction of Retroviral Vectors Retroviral vectors useful in the methods of this invention are produced recombinantly by procedures already taught in the art. For example, WO
94/29438 describes the construction of retroviral packaging plasmids and packaging cell lines. As is apparent to the skilled artisan, the retroviral vectors useful in the methods of this invention are capable of infecting the cells described herein. The techniques used to construct vectors, and transfix and infect cells are widely practiced in the art. Examples of retroviral vectors are those derived from marine, avian or primate retroviruses. Retroviral vectors based on the Moloney marine leukemia virus (MoMLV) are the most commonly used because of the availability of retroviral variants that efficiently infect human cells. Other suitable vectors include those based on the Gibbon Ape Leukemia Virus (GAL) or HIV.
In producing retroviral vector constructs derived from the Moloney marine leukemia virus (MoMLV), in most cases, the viral gag, pol and env sequences are removed from the virus, creating room for insertion of foreign DNA sequences.
. Genes encoded by the foreign DNA are usually expressed under the control of the w strong viral promoter in the LTR. Such a construct can be packed into viral particles effciently if the gag, pol and env functions are provided in traps by a packaging cell line. Thus, when the vector construct is introduced into the packaging cell, the gag-pol and env proteins produced by the cell, assemble with the vector RNA to produce infectious virions that are secreted into the culture medium. The virus thus produced can infect and integrate into the DNA of the target cell, but does not produce infectious viral particles since it is lacking essential packaging sequences. Most of the packaging cell lines currently in use have been transfected with separate plasmids, each containing one of the necessary coding sequences, so that multiple recombination events are necessary before a replication competent virus can be produced. Alternatively, the packaging cell line harbors an integrated provirus. The provirus has been crippled so that, although it produces all the proteins required to assemble infectious viruses, its own RNA cannot be packaged into virus. Instead, RNA produced from the recombinant virus is packaged. The virus stock released from the packaging cells thus contains only recombinant virus.
The range of host cells that may be infected by a retrovirus or retroviral vector is determined by the viral envelope protein. The recombinant virus can be used to infect virtually any other cell type recognized by the env protein provided by the packaging cell, resulting in the integration of the viral genome in the transduced cell and the stable production of the foreign gene product. In general, marine ecotropic env of MoMLV allows infection of rodent cells, whereas amphotropic env allows infection of rodent, avian and some primate cells, including human cells. Amphotropic packaging cell lines for use with MoMLV
systems are known in the art and commercially available and include, but are not limited to, PA12 and PA317. Miller et al. (1985) Mol. Cell. Biol. 5:431-437;
Miller et al. (1986) Mol. Cell. Biol. 6:2895-2902; and Danos et al. (1988) Proc.
Natl. Acad. Sci. USA 85:6460-6464. Xenotropic vector systems exist which also allow infection of human cells.
The host range of retroviral vectors has been altered by substituting the env protein of the base virus with that of a second virus. The resulting, "pseudotyped" virus has the host range of the virus donating the envelope protein and expressed by the packaging cell line. Recently, the G-glycoprotein from vesicular stomatitis virus (VSV-G) has been substituted for the MoMLV env protein. Burns et al. (1993) Proc. Natl. Acad. Sci. USA 90:8033-8037 and PCT patent application WO 92/14829. Since infection is not dependent on a specific receptor, VSV-G pseudotyped vectors have a broad host range.
Usually, the vectors will contain at least two heterologous genes or gene sequences: (i) the therapeutic gene to be transferred; and (ii) a marker gene that enables tracking of infected cells. As used herein, "therapeutic gene" can be an entire gene or only the functionally active fragment of the gene capable of compensating for the deficiency in the patient that arises from the defective endogenous gene. Therapeutic gene also encompasses antisense oligonucleotides or genes useful for antisense suppression and ribozymes for ribozyme-mediated therapy. For example, in the present invention, a therapeutic gene may be one that neutralizes the immunosuppressive factor or counter its effects.
Therapeutic genes that encode dominant inhibitory oligonucleotides and peptides as well as genes that encode regulatory proteins and oligonucleotides also are encompassed by this invention. Generally, gene therapy will involve the transfer of a single therapeutic gene although more than one gene may be necessary for the treatment of particular diseases. In one embodiment, the therapeutic gene is a dominant inhibiting mutant of the wild-type immunosuppressive agent. Alternatively, the therapeutic gene could be a wild-type, copy of a defective gene or a functional homologue.
More than one gene can be administered per vector or alternatively, more than one gene can be delivered using several compatible vectors. Depending on the genetic defect, the therapeutic gene can include the regulatory and untranslated sequences. For gene therapy in human patients, the therapeutic gene will generally be of human origin although genes from other closely related species that exhibit high homology and biologically identical or equivalent function in humans may be used, if the gene product does not induce an adverse immune reaction in the recipient. The therapeutic gene suitable for use in treatment will vary with the disease.
Nucleotide sequences for the therapeutic gene will generally be known in the art or can be obtained from various sequence databases such as GenBank.
The therapeutic gene itself will generally be available or can be isolated and cloned using the polymerase chain reaction PCR (Perkin-Elmer) and other standard recombinant techniques. The skilled artisan will readily recognize that any therapeutic gene can be excised as a compatible restriction fragment and placed in a vector in such a manner as to allow proper expression of the therapeutic gene in hematopoietic cells.
A marker gene can be included in the vector for the purpose of monitoring successful transduction and for selection of cells into which the DNA has been integrated, as against cells which have not integrated the DNA construct.
Various marker genes include, but are not limited to, antibiotic resistance markers, such as resistance to 6418 or hygromycin. Less conveniently, negative selection may be used, including, but not limited to, where the marker is the HSV-tk gene, which will make the cells sensitive to agents such as acyclovir and gancyclovir.
Alternatively, selections could be accomplished by employment of a stable cell surface marker to select for transgene expressing cells by FACS sorting. The Neon (neomycin /G418 resistance) gene is commonly used but any convenient marker gene whose sequences are not already present in the recipient cell, can be used.
The viral vector can be modified to incorporate chimeric envelope proteins or nonviral membrane proteins into retroviral particles to improve particle stability and expand the host range or to permit cell type-specific targeting during infection. The production of retroviral vectors that have altered host range is taught, for example, in WO 92/14829 and WO 93/14188. Retroviral vectors that can target specific cell types in vivo are also taught, for example, in Kasahara et al.
(1994) Science 266:1373-1376. Kasahara, et al. describe the construction of a Moloney leukemia virus (MoMLV) having a chimeric envelope protein consisting of human erythropoietin (EPO) fused with the viral envelope protein. This hybrid virus shows tissue tropism for human red blood progenitor cells that bear the receptor for EPO, and is therefore useful in gene therapy of sickle cell anemia and thalassemia. Retroviral vectors capable of specifically targeting infection of cells are preferred for in vivo gene therapy.
The viral constructs can be prepared in a variety of conventional ways.
Numerous vectors are now available which provide the desired features, such as long terminal repeats, marker genes, and restriction sites, which may be further modified by techniques known in the art. The constructs may encode a signal peptide sequence to ensure that cell surface or secreted proteins encoded by genes are properly processed post-translationally and expressed on the cell surface if appropriate. Preferably, the foreign genes) is under the control of a cell specific promoter.
Expression of the transferred gene can be controlled in a variety of ways depending on the purpose of gene transfer and the desired effect. Thus, the introduced gene may be put under the control of a promoter that will cause the gene to be expressed constitutively, only under specific physiologic conditions, or in particular cell types.
The retroviral LTR (long terminal repeat) is active in most hematopoietic cells in vivo and will generally be relied upon for transcription of the inserted sequences and their constitutive expression (Ohashi et al. (1992) Proc. Natl.
Acad.
Sci. USA 89:11332; Correll et al. (1992) Blood 80:331). Other suitable promoters include the human cytomegalovirus (CMV) immediate early promoter and the U3 region promoter of the Moloney Murine Sarcoma Virus (MMSV), Rous Sarcoma Virus (RSV) or Spleen Focus Forming Virus (SFFV).
Examples of promoters that may be used to cause expression of the introduced sequence in specific cell types include Granzyme A for expression in T-cells and NK cells, the CD34 promoter for expression in stem and progenitor w cells, the CD8 promoter for expression in cytotoxic T-cells, and the CD 11 b promoter for expression in myeloid cells.
Inducible promoters may be used for gene expression under certain physiologic conditions. For example, an electrophile response element may be used to induce expression of a chemoresistance gene in response to electrophilic molecules. The therapeutic benefit may be further increased by targeting the gene product to the appropriate cellular location, for example the nucleus, by attaching the appropriate localizing sequences.
The vector construct is introduced into a packaging cell line which will generate infectious virions. Packaging cell lines capable of generating high titers of replication-defective recombinant viruses are known in the art, see for example, WO 94/29438. Viral particles are harvested from the cell supernatant and purified for in vivo infection using methods known in the art such as by filtration of supernatants 48 hours post transfection. The viral titer is determined by infection of a constant number of appropriate cells (depending on the retrovirus) with titrations of viral supernatants. The transduction efficiency can be assayed hours later by a variety of methods, including Southern blotting.
After viral transduction, the presence of the viral vector in the transduced cells or their progeny can be verified such as by PCR. PCR can be performed to detect the marker gene or other virally transduced sequences. Generally, periodic blood samples are taken and PCR conveniently performed using it Neon probes if the Neon gene is used as marker. The presence of virally transduced sequences in bone marrow cells or mature hematopoietic cells is evidence of successful reconstitution by the transduced cells. PCR techniques and reagents are well known in the art, See, generally, PCR PROTOCOLS, A GUIDE TO METHODS AND
APPLICATIONS. Innis, Gelfand, Sninsky & White, eds. (Academic Press, Inc., San Diego, CA 1990) and commercially available (Perkin-Elmer).
Non-viral vectors, such as plasmid vectors useful in the genetic modifications of this invention, can be produced according to methods taught in the art. References describing the construction of non-viral vectors include the following: Ledley, F.D. (1995) Human Gene Therapy 6:1129-1144, Miller, N.
et al. (1995) FASEB 9:190-199; Chonn, A. et al. (1995) Curr. Opin. Biotech.
6:698-708, Schofield, J.P. et al. (1995) British Med. Bull. 51:56-71; Brigham, K.L.
et al.
(1993) J. Liposome Res. 3:31-49, Brigham, K.L. WO 91/06309; Felgner, P.L. et al.
Color #1: CD3 alone, CD14 alone, etc.; Leu M7 or Leu M9; anti-Class I, etc.
Color #2: HLA-Dq, B7.1, B7.2, CD25 (IL2r), ICAM, LFA-3, etc.
The goal of FACS analysis at the time of collection is to confirm that the DCs are enriched in the expected fractions, to monitor neutrophil contamination, and to make sure that appropriate markers are expressed. This rapid bulk collection of enriched DCs from human peripheral blood, suitable for clinical applications, is absolutely dependent on the analytic FACS technique described above for quality control. If need be, mature DCs can be immediately separated from monocytes at this point by fluorescent sorting for "cocktail negative"
cells.
It may not be necessary to routinely separate DCs from monocytes because, as will be detailed below, the monocytes themselves are still capable of differentiating into DCs or functional DC-like cells in culture.
Once collected, the DC rich/monocyte APC fractions (usually 150 through 190) can be pooled and cryopreserved for future use, or immediately placed in short term culture.
Alternatively, others have reported that a method for upregulating (activating) dendritic cells and converting monocytes to an activated dendritic cell phenotype. This method involves the addition of calcium ionophore to the culture media convert monocytes into activated dendritic cells. Adding the calcium ionophore A23187, for example, at the beginning of a 24-48 hour culture period resulted in uniform activation and dendritic cell phenotypic conversion of the pooled "monocyte plus DC" fractions: characteristically, the activated population becomes uniformly CD14 (Leu M3) negative, and upregulates HLA-DR, HLA-DQ, ICAM-1, B7.1, and B7.2. Furthermore this activated bulk population functions as well on a small numbers basis as a further purified.
Specific combinations) of cytokines have been used successfully to amplify (or partially substitute) for the activation/conversion achieved with calcium ionophore: these cytokines include but are not limited to rhGM-CSF, rhIL-2, and rhIL-4. Each cytokine when given alone is inadequate for optimal upregulation.
In one embodiment, the APCs and cells expressing one or more antigens are autologous. In another embodiment, the APCs and cells expressing the antigen are allogeneic, i.e., derived from a different subject.
Administration of APC recruitment or proliferation Factors) In one embodiment, an APC-recruitment or proliferation factor is administered to mice by subcutaneous injection. The APC-recruitment or proliferation factors is administered either as a protein or as a gene therapy vector that is capable of expressing the gene for the APC-enhancing factor. The effective amount can be readily determined, for instance by administering subcutaneous injections at different dosages and evaluating the subsequent inflammatory response at different times after administration.
The APC recruitment or proliferation factors useful in the present invention include, but are not limited to, GM-CSF, PRL, Sepragel, Ad2/cmvGMCSFF9ix, and Ad2/EV/PRL. In addition, it may be necessary to complex the protein form of some of the CEFs to a bead for slow-release into the tissue (Meyer et al. (1994) Biochem. Biophys. Res. Common. 199:433-438;
Tanaka et al. (1991) Cancer Res. 51:3710-3714). The slow release of chemotactic factors establishes a concentration gradient that would facilitate dendritic cell migration towards the APC recruitment or proliferation factor.
An in vitro assay to determine the recruitment efficacy of known or novel APC recruitment factors is the chemotactic assay for cultured dendritic cells as described by Godiska et al. (1997) J. Exp. Med. 185:1595-1604; Morelli et al.
(1996) Immunology 89:126-134; and Sozzani et al. (1995) J. Immunol. 155:3292-3295.
The inflammatory response at the site of APC recruitment or proliferation factor administration can be evaluated by any other known method, for example, in histology sections or in samples taken by needle aspiration. Alternatively, enhanced numbers of dendritic cells, Langerhans cells, and other antigen presenting cells can also be evaluated using either immunohistochemistry or FACS analysis (Kaplan et al. (1992), supra and Tazi et al. (1993) J. Clin.
Invest.
91:566-576).
Alternative routes of administration for gene therapy vectors expressing APC recruitment or proliferation factors are also encompassed by the present invention, and are discussed in detail below. By way of example only, topical administration of recombinant adenoviral vectors to debrided skin (Tang et al.
( 1997) Nature 388:729-730) and gene gun delivery of adenoviral or plasmid vectors (Mahvi et al. (1997) Immunol. Cell. Biol. 75:456-460) can be employed.
The subsequent inflammatory response will be evaluated and compared with the response from the subcutaneous administration.
Administration of Tumor-Associated Antigens ('TAA) Tumor-associated antigens (TAA) can be administered as whole molecules or, preferably, using gene delivery vehicles carrying a polynucleotide encoding the TAA. TAAs may also be administered to APC recruitment or proliferation factor-primed subcutaneous sites in the form of peptides or recombinant proteins.
Typically, gene delivery vehicles expressing a TAA will be administered after treatment with the APC recruitment or proliferation factor. In one aspect, the S TAA is administered in a recombinant adenoviral vector or cationic lipid:DNA
vectors by subcutaneous injection. The TAAs include, but are not limited to, Ad2gp 100; GL67:pCF 1 gp 100; Ad2TRP2; and GL67:pCF 1 TRP2.
The successful transfer of the TAA transgene to APCs, such as dendritic cells or Langerhans cells, at the site of vector administration may be evaluated by any suitable method, for example, using a combination of fluorescence in situ hybridization (FISH) (Gussoni et al. (1996) Nature Biotechnol. 14:1012-1016);
fluorescently labeled lipids or plasmid DNA (Bebok et al. (1996) J. Pharmacol.
Exp. Therapeutics 279:1462-1469 and Matsui et al. (1997) J. Biol. Chem.
272:1117-1126); and immunofluorescence. Transfection of these cell types will also be analyzed by measuring the induction of a specific CTL response against the TAAs (Chen et al. (1993) J. Immunol. 151:244-255). Optimization of transfection conditions will include changes in dose and time after APC
recruitment or proliferation factor administration.
Presentation of Antigen to the APC
Peptide fragments from antigens must first be bound to peptide binding receptors ((MHC) class I and class II molecules) that display the antigenic peptides on the surface of the APCs. Palmer E. and Cresswell ( 1998) Annu.
Rev.
Immunol. 16:323 and Germain R.N. (1996) Immunol. Rev. 151:5. T lymphocytes produce an antigen receptor that they use to monitor the surface of APCs for the presence of foreign peptides. The antigen receptors on TH cells recognize antigenic peptides bound to MHC class II molecules whereas the receptors on CTLs react with antigens displayed on class I molecules. For a general review of the methods for presentation of exogenous antigen by APC, see Raychaudhuri and Rock (1998) Nature Biotechnology 16:1025.
For purposes of immunization, antigens can be delivered to antigen-presenting cells as protein/peptide or in the form of polynucleotides encoding the protein/peptide ex vivo or in vivo. The methods described below focus primarily on DCs which are the most potent, preferred APCs.
Several different techniques have been described to produce genetically modified APCs. These include: (1) the introduction into the APCs of polynucleotides that express antigen or fragments thereof; (2) infection of APCs with recombinant vectors to induce endogenous expression of antigen; and (3) introduction of tumor antigen into the DC cytosol using liposomes. (See Boczkowski D. et al. (1996) J. Exp. Med. 184:465; Rouse et al. (1994) J.
Virol.
68:5685; and Nair et al. (1992) J. Exp. Med. 175:609). For the purpose of this invention, any method which allows for the introduction and expression of the heterologous, altered or non-self antigen and presentation by the MHC on the surface of the APC is within the scope of this invention.
Antigen Pulsing Pulsing is accomplished in vitro%x vivo by exposing APCs to antigenic protein or peptide(s). The protein or peptides) are added to APCs at a concentration of 1-10 Nm for approximately 3 hours. Paglia et al. (1996) J.
Exp.
Med. 183:317, has shown that APC incubated with whole protein in vitro were recognized by MHC class I-restricted CTLs, and that immunization of animals with these APCs led to the development of antigen-specific CTLs in vivo.
Protein/peptide antigen can also be delivered to APC in vivo and presented by the APC. Antigen is preferably delivered with adjuvant via the intravenous, subcutaneous, intranasal, intramuscular or intraperitoneal route of delivery.
Grant E.P. and Rock K.L. (1992) J. Immunol. 148:13; Norbury, C. C. et al. (1995) Immunity 3:783; and Reise-Sousa C. and Germain R.N. (1995) J. Exp. Med.
182:841.
Wp 99/47179 PCT/US99/06071 Antigen Painting Another method which can be used is termed "painting". It has been demonstrated that glycosyl-phosphotidylinositol (GPI)-modified proteins possess the ability to reincorporate themselves back into cell membranes after purification. Hirose et al. (1995) Methods Enzymol. 250:582; Medof et al:
(1984) J. Exp. Med. 160:1558; Medof (1996) FASEB J. 10:574; and Huang et al. (1994) Immunity 1:607, have exploited this property in order to create APCs of specific composition for the presentation of antigen to CTLs. Expression vectors for ~i2-microglobulin and the HLA-A2.1 allele were first devised. The proteins were expressed in Schneider S2 Drosophila melanogaster cells, known to support GPI-modification. After purification, the proteins could be incubated together with a purified antigenic peptide which resulted in a trimolecular complex capable of efficiently inserting itself into the membranes of autologous cells. In essence, these protein mixtures were used to "paint" the APC surface, conferring the ability to stimulate a CTL clone that was specific for the antigenic peptide. Cell coating was shown to occur rapidly and to be protein concentration dependent. This method of generating APCs bypasses the need for gene transfer into the APC and permits control of antigenic peptide densities at the cell surfaces.
Foster Antigen Presenting Cells Foster APCs are derived from the human .dell line 174xCEM.T2, referred to as T2, which contains a mutation in its antigen processing pathway that restricts the association of endogenous peptides with cell surface MHC class I molecules (Zweerink et al. (1993} J. Immunol. 150:1763). This is due to a large homozygous deletion in the MHC class II region encompassing the genes TAP1, TAP2, LMP1, and LMP2, which are required for antigen presentation to MHC
class 1-restricted CD8+ CTLs. In effect, only "empty" MHC class I molecules are presented on the surface of these cells. Exogenous peptide added to the culture medium binds to these MHC molecules provided that the peptide contains the allele-specific binding motif. These T2 cells are referred to herein as "foster"
APCs. They can be used in conjunction with this invention to present the heterologous, altered or control antigen.
Transduction of T2 cells with specific recombinant MHC alleles allows for redirection of the MHC restriction profile. Libraries tailored to the recombinant allele will be preferentially presented by them because the anchor residues will prevent efficient binding to the endogenous allele.
High level expression of MHC molecules makes the APC more visible to the CTLs. Expressing the MHC allele of interest in T2 cells using a powerful transcriptional promoter (e.g., the CMV promoter) results in a more reactive APC
(most likely due to a higher concentration of reactive MHC-peptide complexes on the cell surface).
Preparation of Hybrid Cells Utilizing Dendritic Cells Hybrid cells typically retain the phenotypic characteristics of the APCs.
Thus, hybrids made with dendritic cells will express the same MHC class II
proteins and other cell surface markers. Moreover, the hybrids will express those antigens expressed on the cells from which they are derived.
A population of APCs are collected and isolated. Preferably, the ratio of APCs:antigen-expressing cells is between about 1:100 and about 1000:1. For example, in one aspect, the fraction enriched for antigen-expressing cells.is then fused to APCs, preferably dendritic cells. Fusion between the APCs and antigen-expressing cells can be carried out with any suitable method, for example using polyethylene glycol (PEG) or Sendia virus. In a preferred embodiment, the hybrid cells are created using the procedure described by Gong et al.(1997) Nat. Med.
3(5):558-561.
Typically, unfused cells will die off after a few days in culture. Therefore, the fused cells can be separated from the parent cells simply by allowing the culture to grow for several days. In this embodiment, the hybrid cells both survive more and, additionally, are only lightly adherent to tissue culture surfaces.
The parent cells are strongly adherent to the containers. Therefore, after about 5 to 10 days in culture, the hybrid cells can be gently dislodged and transferred to new containers, while the unfused cells remained attached.
Alternatively, it has been shown that fused cells lack functional hypoxanthine-guaninephosphoribosyl transferase ("HGPRT") enzyme and are, therefore, resistant to treatment with the compound HAT. Accordingly, to select these cells HAT can be added to the culture media. However, unlike conventional HAT selection, hybrid cell cultures should not be exposed to the compound for more than 12 days.
Gene Delivery Vehicles In general, introduction of the transgene or polynucleotide encoding the APC recruitment or proliferation factor or antigen is accomplished in vivo, ex vivo or in vitro by introducing a vector containing a polynucieotide or transgene encoding a heterologous or an altered antigen or APC recruitment or proliferation factor. A variety of different gene transfer vectors, including viral as well as non-viral systems can be used. Viral vectors useful in the genetic modifications of this invention include, but are not limited to adenovirus, adeno-associated virus vectors, retroviral vectors and adeno-retroviral chimeric vectors.
Construction of Recombinant Adenoviral Vectors or Adeno-Associated Virus Vectors Adenovirus and adeno-associated virus vectors useful in the genetic modifications of this invention may be produced according to methods already taught in the art. (see, e.g., Karlsson et al. (1986) EMBO 5:2377; Carter (1992) Curr. Op. Biotechnol. 3:533-539; Muzcyzka (1992) Current Top. Microbiol.
Immunol. 158:97-129; GENE TARGETING: A PRACTICAL APPROACH (1992) ed. A.
L. Joyner, Oxford University Press, NY). Several different approaches are feasible. Preferred is the helper-independent replication deficient human adenovirus system.
The recombinant adenoviral vectors based on the human adenovirus 5 (Virology 163:614-617, 1988) are missing essential early genes from the adenoviral genome (usually ElA/E1B), and are therefore unable to replicate unless grown in permissive cell lines that provide the missing gene products in traps. In place of the missing adenoviral genomic sequences, a transgene of interest can be cloned and expressed in cells infected with the replication deficient adenovirus. Although adenovirus-based gene transfer does not result in integration of the transgene into the host genome (less than 0.1 % adenovirus-mediated transfections result in transgene incorporation into host DNA), and therefore is not stable, adenoviral vectors can be propagated in high titer and transfect non-replicating cells. Human 293 cells, which are human embryonic kidney cells transformed with adenovirus E 1 A/E 1 B genes, typify useful permissive cell lines and are commercially available from the ATCC. However, other cell lines which allow replication-deficient adenoviral vectors to propagate therein can be used, including HeLa cells.
Additional references describing adenovirus vectors and other viral vectors which could be used in the methods of the present invention include the following: Horwitz M.S. Adenoviridae and Their Replication, in Fields B. et al.
(eds.) VIROLOGY, Vol. 2, Raven Press New York, pp. 1679-1721,1990);
Graham, F. et al., pp. 109-128 in METHODS IN MOLECULAR BIOLOGY, Vol. 7: GENE
TRANSFER AND EXPRESSION PROTOCOLS, Murray, E. (ed.), Humana Press, Clifton, N.J. (1991); Miller, N. et al. (1995) FASEB Journal 9:190-199 Schreier, H.
(1994) Pharmaceutics Acta Helvetiae 68:145-159; Schneider and French (1993) Circulation 88:1937-1942; Curiel, D.T. et al. (1992) Human Gene Therapy 3: 147-154;
Graham, F.L. et al., WO 95/00655; Falck-Pedersen, E.S. WO 95/16772; Denefle, P.
et al. WO 95/23867; Haddada, H. et al. WO 94/26914; Perricaudet, M. et al.
WO 95/02697; and Zhang, W. et al. WO 95/25071. A variety of adenovirus plasmids are also available from commercial sources, including, e.g., Microbix Biosystems of Toronto, Ontario, Canada (see, e.g., Microbix Product Information Sheet: Plasmids for Adenovirus Vector Construction, 1996). See also, the papers by Vile et al. (1997) Nature Biotech. 15:840-841; Feng et al. (1997) Nature Biotech. 15:866-870, describing the construction and use of adeno-retroviral chimeric vectors that can be employed for genetic modifications.
Additional references describing AAV vectors which could be used in the methods of the present invention include the following: Carter B., HANDBOOK of PARVOVIRUSES, Vol. I, pp. 169-228, 1990; Berns, VIROLOGY, pp. 1743-1764 (Raven Press 1990); Carter, B. (1992) Curr. Opin. Biotechnol. 3:533-539;
Muzyczka N. (1992) Current Topics in Micro. and Immunol. 158:92-129;
Flotte, T.R. et al. (1992) Am. J. Respir. Cell Mol. Biol. 7:349-356;
Chatterjee et al. (1995) Ann. NY Acad. Sci. 770:79-90; Flotte, T.R. et al. WO 95/13365;
Trempe, J.P. et al. WO 95/13392; Kotin, R. (1994) Human Gene Therapy, 5:793-801; Flotte, T.R. et al. (1995) Gene Therapy 2:357-362; Allen, J.M.
WO 96/17947; and Du et al. (1996) Gene Therapy 3:254-261.
Construction of Retroviral Vectors Retroviral vectors useful in the methods of this invention are produced recombinantly by procedures already taught in the art. For example, WO
94/29438 describes the construction of retroviral packaging plasmids and packaging cell lines. As is apparent to the skilled artisan, the retroviral vectors useful in the methods of this invention are capable of infecting the cells described herein. The techniques used to construct vectors, and transfix and infect cells are widely practiced in the art. Examples of retroviral vectors are those derived from marine, avian or primate retroviruses. Retroviral vectors based on the Moloney marine leukemia virus (MoMLV) are the most commonly used because of the availability of retroviral variants that efficiently infect human cells. Other suitable vectors include those based on the Gibbon Ape Leukemia Virus (GAL) or HIV.
In producing retroviral vector constructs derived from the Moloney marine leukemia virus (MoMLV), in most cases, the viral gag, pol and env sequences are removed from the virus, creating room for insertion of foreign DNA sequences.
. Genes encoded by the foreign DNA are usually expressed under the control of the w strong viral promoter in the LTR. Such a construct can be packed into viral particles effciently if the gag, pol and env functions are provided in traps by a packaging cell line. Thus, when the vector construct is introduced into the packaging cell, the gag-pol and env proteins produced by the cell, assemble with the vector RNA to produce infectious virions that are secreted into the culture medium. The virus thus produced can infect and integrate into the DNA of the target cell, but does not produce infectious viral particles since it is lacking essential packaging sequences. Most of the packaging cell lines currently in use have been transfected with separate plasmids, each containing one of the necessary coding sequences, so that multiple recombination events are necessary before a replication competent virus can be produced. Alternatively, the packaging cell line harbors an integrated provirus. The provirus has been crippled so that, although it produces all the proteins required to assemble infectious viruses, its own RNA cannot be packaged into virus. Instead, RNA produced from the recombinant virus is packaged. The virus stock released from the packaging cells thus contains only recombinant virus.
The range of host cells that may be infected by a retrovirus or retroviral vector is determined by the viral envelope protein. The recombinant virus can be used to infect virtually any other cell type recognized by the env protein provided by the packaging cell, resulting in the integration of the viral genome in the transduced cell and the stable production of the foreign gene product. In general, marine ecotropic env of MoMLV allows infection of rodent cells, whereas amphotropic env allows infection of rodent, avian and some primate cells, including human cells. Amphotropic packaging cell lines for use with MoMLV
systems are known in the art and commercially available and include, but are not limited to, PA12 and PA317. Miller et al. (1985) Mol. Cell. Biol. 5:431-437;
Miller et al. (1986) Mol. Cell. Biol. 6:2895-2902; and Danos et al. (1988) Proc.
Natl. Acad. Sci. USA 85:6460-6464. Xenotropic vector systems exist which also allow infection of human cells.
The host range of retroviral vectors has been altered by substituting the env protein of the base virus with that of a second virus. The resulting, "pseudotyped" virus has the host range of the virus donating the envelope protein and expressed by the packaging cell line. Recently, the G-glycoprotein from vesicular stomatitis virus (VSV-G) has been substituted for the MoMLV env protein. Burns et al. (1993) Proc. Natl. Acad. Sci. USA 90:8033-8037 and PCT patent application WO 92/14829. Since infection is not dependent on a specific receptor, VSV-G pseudotyped vectors have a broad host range.
Usually, the vectors will contain at least two heterologous genes or gene sequences: (i) the therapeutic gene to be transferred; and (ii) a marker gene that enables tracking of infected cells. As used herein, "therapeutic gene" can be an entire gene or only the functionally active fragment of the gene capable of compensating for the deficiency in the patient that arises from the defective endogenous gene. Therapeutic gene also encompasses antisense oligonucleotides or genes useful for antisense suppression and ribozymes for ribozyme-mediated therapy. For example, in the present invention, a therapeutic gene may be one that neutralizes the immunosuppressive factor or counter its effects.
Therapeutic genes that encode dominant inhibitory oligonucleotides and peptides as well as genes that encode regulatory proteins and oligonucleotides also are encompassed by this invention. Generally, gene therapy will involve the transfer of a single therapeutic gene although more than one gene may be necessary for the treatment of particular diseases. In one embodiment, the therapeutic gene is a dominant inhibiting mutant of the wild-type immunosuppressive agent. Alternatively, the therapeutic gene could be a wild-type, copy of a defective gene or a functional homologue.
More than one gene can be administered per vector or alternatively, more than one gene can be delivered using several compatible vectors. Depending on the genetic defect, the therapeutic gene can include the regulatory and untranslated sequences. For gene therapy in human patients, the therapeutic gene will generally be of human origin although genes from other closely related species that exhibit high homology and biologically identical or equivalent function in humans may be used, if the gene product does not induce an adverse immune reaction in the recipient. The therapeutic gene suitable for use in treatment will vary with the disease.
Nucleotide sequences for the therapeutic gene will generally be known in the art or can be obtained from various sequence databases such as GenBank.
The therapeutic gene itself will generally be available or can be isolated and cloned using the polymerase chain reaction PCR (Perkin-Elmer) and other standard recombinant techniques. The skilled artisan will readily recognize that any therapeutic gene can be excised as a compatible restriction fragment and placed in a vector in such a manner as to allow proper expression of the therapeutic gene in hematopoietic cells.
A marker gene can be included in the vector for the purpose of monitoring successful transduction and for selection of cells into which the DNA has been integrated, as against cells which have not integrated the DNA construct.
Various marker genes include, but are not limited to, antibiotic resistance markers, such as resistance to 6418 or hygromycin. Less conveniently, negative selection may be used, including, but not limited to, where the marker is the HSV-tk gene, which will make the cells sensitive to agents such as acyclovir and gancyclovir.
Alternatively, selections could be accomplished by employment of a stable cell surface marker to select for transgene expressing cells by FACS sorting. The Neon (neomycin /G418 resistance) gene is commonly used but any convenient marker gene whose sequences are not already present in the recipient cell, can be used.
The viral vector can be modified to incorporate chimeric envelope proteins or nonviral membrane proteins into retroviral particles to improve particle stability and expand the host range or to permit cell type-specific targeting during infection. The production of retroviral vectors that have altered host range is taught, for example, in WO 92/14829 and WO 93/14188. Retroviral vectors that can target specific cell types in vivo are also taught, for example, in Kasahara et al.
(1994) Science 266:1373-1376. Kasahara, et al. describe the construction of a Moloney leukemia virus (MoMLV) having a chimeric envelope protein consisting of human erythropoietin (EPO) fused with the viral envelope protein. This hybrid virus shows tissue tropism for human red blood progenitor cells that bear the receptor for EPO, and is therefore useful in gene therapy of sickle cell anemia and thalassemia. Retroviral vectors capable of specifically targeting infection of cells are preferred for in vivo gene therapy.
The viral constructs can be prepared in a variety of conventional ways.
Numerous vectors are now available which provide the desired features, such as long terminal repeats, marker genes, and restriction sites, which may be further modified by techniques known in the art. The constructs may encode a signal peptide sequence to ensure that cell surface or secreted proteins encoded by genes are properly processed post-translationally and expressed on the cell surface if appropriate. Preferably, the foreign genes) is under the control of a cell specific promoter.
Expression of the transferred gene can be controlled in a variety of ways depending on the purpose of gene transfer and the desired effect. Thus, the introduced gene may be put under the control of a promoter that will cause the gene to be expressed constitutively, only under specific physiologic conditions, or in particular cell types.
The retroviral LTR (long terminal repeat) is active in most hematopoietic cells in vivo and will generally be relied upon for transcription of the inserted sequences and their constitutive expression (Ohashi et al. (1992) Proc. Natl.
Acad.
Sci. USA 89:11332; Correll et al. (1992) Blood 80:331). Other suitable promoters include the human cytomegalovirus (CMV) immediate early promoter and the U3 region promoter of the Moloney Murine Sarcoma Virus (MMSV), Rous Sarcoma Virus (RSV) or Spleen Focus Forming Virus (SFFV).
Examples of promoters that may be used to cause expression of the introduced sequence in specific cell types include Granzyme A for expression in T-cells and NK cells, the CD34 promoter for expression in stem and progenitor w cells, the CD8 promoter for expression in cytotoxic T-cells, and the CD 11 b promoter for expression in myeloid cells.
Inducible promoters may be used for gene expression under certain physiologic conditions. For example, an electrophile response element may be used to induce expression of a chemoresistance gene in response to electrophilic molecules. The therapeutic benefit may be further increased by targeting the gene product to the appropriate cellular location, for example the nucleus, by attaching the appropriate localizing sequences.
The vector construct is introduced into a packaging cell line which will generate infectious virions. Packaging cell lines capable of generating high titers of replication-defective recombinant viruses are known in the art, see for example, WO 94/29438. Viral particles are harvested from the cell supernatant and purified for in vivo infection using methods known in the art such as by filtration of supernatants 48 hours post transfection. The viral titer is determined by infection of a constant number of appropriate cells (depending on the retrovirus) with titrations of viral supernatants. The transduction efficiency can be assayed hours later by a variety of methods, including Southern blotting.
After viral transduction, the presence of the viral vector in the transduced cells or their progeny can be verified such as by PCR. PCR can be performed to detect the marker gene or other virally transduced sequences. Generally, periodic blood samples are taken and PCR conveniently performed using it Neon probes if the Neon gene is used as marker. The presence of virally transduced sequences in bone marrow cells or mature hematopoietic cells is evidence of successful reconstitution by the transduced cells. PCR techniques and reagents are well known in the art, See, generally, PCR PROTOCOLS, A GUIDE TO METHODS AND
APPLICATIONS. Innis, Gelfand, Sninsky & White, eds. (Academic Press, Inc., San Diego, CA 1990) and commercially available (Perkin-Elmer).
Non-viral vectors, such as plasmid vectors useful in the genetic modifications of this invention, can be produced according to methods taught in the art. References describing the construction of non-viral vectors include the following: Ledley, F.D. (1995) Human Gene Therapy 6:1129-1144, Miller, N.
et al. (1995) FASEB 9:190-199; Chonn, A. et al. (1995) Curr. Opin. Biotech.
6:698-708, Schofield, J.P. et al. (1995) British Med. Bull. 51:56-71; Brigham, K.L.
et al.
(1993) J. Liposome Res. 3:31-49, Brigham, K.L. WO 91/06309; Felgner, P.L. et al.
4; Solodin et al. (1995) Biochem. 34:13537-13544; WO 93/19768;
Debs et al. WO 93/25673; Felgner, P.L. et al. U.S. Patent 5,264,618; Epand, R.M.
et al. U.S. Patent 5,283,185; Gebeyehu et al. U.S. Patent 5,334,761; Felgner, P.L.
et al. U.S. Patent 5,459,127; Overell, R.W. et al. WO 95/28494; Jessee WO
95/02698; Haces and Ciccarone WO 95/17373; and Lin et al. WO 96/01840.
Vaccines The agents identified herein as effective for their intended purpose can be administered to subjects or individuals susceptible to or at risk of developing a disease, such as cancer. When the agent is administered to a subject such as a mouse, a rat or a human patient, the agent can be added to a pharmaceutically acceptable Garner and systemically or topically administered to the subject.
To determine patients that can be beneficially treated, a tumor regression can be assayed. Therapeutic amounts can be empirically determined and will vary with the pathology being treated, the subject being treated and the efficacy and toxicity of the therapy. When delivered to an animal, the method is useful to further confirm efficacy of the agent. As an example, an adenoviral vector encoding a tumor antigen can be employed in vivo for direct immunization as described in Zhai et al. (1996) J. Immunol. 156:700-10. C57BL/6 mice are injected subcutaneously at two sites ( 1.5 x 109 IU per site) with an adenoviral vector encoding an antigen presenting cell recruitment or proliferation factor such as IL4.
Two days later an adenoviral vector encoding a tumor antigen such as gp100 is injected into these two pre-treated site (1.5 x 109 IU per site). Two weeks later, animals are challenged with a lethal dose (2 x 104) of marine B 16F 10 melanoma tumor cells by subcutaneous injection. Animals are scored for survival and tumor measurements are taken.
Administration in vivo can be effected in one dose, continuously or intermittently throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the composition used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated.
Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician. Suitable dosage formulations and methods of administering the agents can be found below.
The agents and compositions of the present invention can be used in the manufacture of medicaments and for the treatment of humans and other animals by administration in accordance with conventional procedures, such as an active ingredient in pharmaceutical compositions.
More particularly, an agent of the present invention also referred to herein as the active ingredient, may be administered for therapy by any suitable route including oral, rectal, nasal, topical (including transdermal, aerosol, buccal and sublingual), vaginal, parental (including subcutaneous, intramuscular, intravenous and intradermal) and pulmonary. It will also be appreciated that the preferred route will vary with the condition and age of the recipient, and the disease being treated.
Exam le Enhancement of antigen delivery to antigen presenting cells is tested in marine tumor models where TAAs have been identified. For example, B 16-F 10 melanoma tumor growth in the C57BL/6 mouse strain can be used since the TAAs MART 1 and gp 100 have been identified and offer some protective effect against tumor growth (Zhai et al. (1997) J. Immunother. 20:15-25). An alternative model is the K1735 melanoma cells from the C3H marine strain, where a specific CTL
response against tumor antigens has been shown (Chen et al. (1993), supra).
In another scenario, an APC recruitment or proliferation factor such as IL-4 is injected subcutaneously in the form of a recombinant protein formulated in either cationic lipids, or in a sponge, to allow for sustained slow release of the APC recruitment or proliferation factor at a localized site. At a time point deemed to be optimal for APC recruitment or proliferation (1 to 3 days post injection), an adenoviral vector encoding an antigen such as the melanoma antigen gp100 is injected into the pretreated site to maximize the likelihood that the injected viral particles will contact, and cause gene transfer to APCs. The genetically modified APCs will present tumor antigen derived peptides to the immune system, thereby provoking a potent anti-tumor cell immune response.
It is to be understood that while the invention has been described in conjunction with the above embodiments, that the foregoing description and the following examples are intended to illustrate and not limit the scope of the invention. For example, any of the above-noted compositions and/or methods can be combined with known therapies or compositions. Other aspects, advantages and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.
Debs et al. WO 93/25673; Felgner, P.L. et al. U.S. Patent 5,264,618; Epand, R.M.
et al. U.S. Patent 5,283,185; Gebeyehu et al. U.S. Patent 5,334,761; Felgner, P.L.
et al. U.S. Patent 5,459,127; Overell, R.W. et al. WO 95/28494; Jessee WO
95/02698; Haces and Ciccarone WO 95/17373; and Lin et al. WO 96/01840.
Vaccines The agents identified herein as effective for their intended purpose can be administered to subjects or individuals susceptible to or at risk of developing a disease, such as cancer. When the agent is administered to a subject such as a mouse, a rat or a human patient, the agent can be added to a pharmaceutically acceptable Garner and systemically or topically administered to the subject.
To determine patients that can be beneficially treated, a tumor regression can be assayed. Therapeutic amounts can be empirically determined and will vary with the pathology being treated, the subject being treated and the efficacy and toxicity of the therapy. When delivered to an animal, the method is useful to further confirm efficacy of the agent. As an example, an adenoviral vector encoding a tumor antigen can be employed in vivo for direct immunization as described in Zhai et al. (1996) J. Immunol. 156:700-10. C57BL/6 mice are injected subcutaneously at two sites ( 1.5 x 109 IU per site) with an adenoviral vector encoding an antigen presenting cell recruitment or proliferation factor such as IL4.
Two days later an adenoviral vector encoding a tumor antigen such as gp100 is injected into these two pre-treated site (1.5 x 109 IU per site). Two weeks later, animals are challenged with a lethal dose (2 x 104) of marine B 16F 10 melanoma tumor cells by subcutaneous injection. Animals are scored for survival and tumor measurements are taken.
Administration in vivo can be effected in one dose, continuously or intermittently throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the composition used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated.
Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician. Suitable dosage formulations and methods of administering the agents can be found below.
The agents and compositions of the present invention can be used in the manufacture of medicaments and for the treatment of humans and other animals by administration in accordance with conventional procedures, such as an active ingredient in pharmaceutical compositions.
More particularly, an agent of the present invention also referred to herein as the active ingredient, may be administered for therapy by any suitable route including oral, rectal, nasal, topical (including transdermal, aerosol, buccal and sublingual), vaginal, parental (including subcutaneous, intramuscular, intravenous and intradermal) and pulmonary. It will also be appreciated that the preferred route will vary with the condition and age of the recipient, and the disease being treated.
Exam le Enhancement of antigen delivery to antigen presenting cells is tested in marine tumor models where TAAs have been identified. For example, B 16-F 10 melanoma tumor growth in the C57BL/6 mouse strain can be used since the TAAs MART 1 and gp 100 have been identified and offer some protective effect against tumor growth (Zhai et al. (1997) J. Immunother. 20:15-25). An alternative model is the K1735 melanoma cells from the C3H marine strain, where a specific CTL
response against tumor antigens has been shown (Chen et al. (1993), supra).
In another scenario, an APC recruitment or proliferation factor such as IL-4 is injected subcutaneously in the form of a recombinant protein formulated in either cationic lipids, or in a sponge, to allow for sustained slow release of the APC recruitment or proliferation factor at a localized site. At a time point deemed to be optimal for APC recruitment or proliferation (1 to 3 days post injection), an adenoviral vector encoding an antigen such as the melanoma antigen gp100 is injected into the pretreated site to maximize the likelihood that the injected viral particles will contact, and cause gene transfer to APCs. The genetically modified APCs will present tumor antigen derived peptides to the immune system, thereby provoking a potent anti-tumor cell immune response.
It is to be understood that while the invention has been described in conjunction with the above embodiments, that the foregoing description and the following examples are intended to illustrate and not limit the scope of the invention. For example, any of the above-noted compositions and/or methods can be combined with known therapies or compositions. Other aspects, advantages and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.
Claims (18)
1. A method of recruiting antigen presenting cells to a predetermined site in a subject, comprising administering to the subject an effective amount of an antigen presenting cell (APC) recruitment or proliferation factor to the predetermined site.
2. The method according to claim 1, wherein the APC recruitment or proliferation factor is administered as a protein or peptide.
3. The method according to claim 2, wherein the protein or polypeptide is formulated for slow release.
4. The method according to claim 1, wherein the APC recruitment or proliferation factor is administered in a gene delivery vehicle.
5. The method according to claim 1 or 4, wherein the APC
recruitment or proliferation factor is selected from the group consisting of a proinflammatory agent, a chemotactic agent, a growth factor and a mitogenic factor.
recruitment or proliferation factor is selected from the group consisting of a proinflammatory agent, a chemotactic agent, a growth factor and a mitogenic factor.
6. The method according to claim 5, wherein the APC recruitment or proliferation factor is selected from the group consisting of granulocyte-macrophage colony stimulating factor (GM-CSF), Sepragel, interleukin 4 (IL4) and macrophage inflammatory protein 3 alpha (MIP-3.alpha.).
7. The method according to claim 1 or 4, further comprising administering a compound selected from the group consisting of a growth factor, a cytokine, a co-stimulatory molecule and a mitogenic factor.
8. The method according to claim 7, wherein the compound is administered in a gene delivery vehicle.
9. A method of enhancing presentation of an antigen into antigen presenting cells (APCs) in vivo comprising priming a predetermined site in a subject with an effective amount of an APC recruitment or proliferation factor and administering an effective amount of the transgene at the site.
10. The method according to claim 9, wherein the antigen is administered as a protein, recombinant protein or peptide.
11. The method according to claim 10, wherein the protein or polypeptide is formulated for slow release.
12. The method according to claim 9, wherein the antigen is administered as a polynucleotide encoding the antigen.
13. The method according to claim 9, wherein the antigen is a tumor associated antigen.
14. The method according to claim 12, wherein the tumor associated antigen is selected from the group consisting of gp100, MUC-1, MART-1, HER-2, CEA, PSA, prostate specific membrane antigen (PSMA), tyrosinase, tyrosinase related proteins 1 or 2 (TRP-1 and TRP-2), NY-ESO-1, and GA733 antigen.
15. The method according to claim 9 or 12, wherein the APC
recruitment or proliferation factor is selected from the group consisting of a proinflammatory agent, a chemotactic agent, a growth factor and a mitogenic factor.
recruitment or proliferation factor is selected from the group consisting of a proinflammatory agent, a chemotactic agent, a growth factor and a mitogenic factor.
16. The method according to claim 9 or 12, wherein the APC
recruitment or proliferation factor is selected from the group consisting of granulocyte-macrophage colony stimulating factor (GM-CSF), Sepragel, interleukin 4 (IL4) and macrophage inflammatory protein 3 alpha (MIP-3.alpha.).
recruitment or proliferation factor is selected from the group consisting of granulocyte-macrophage colony stimulating factor (GM-CSF), Sepragel, interleukin 4 (IL4) and macrophage inflammatory protein 3 alpha (MIP-3.alpha.).
17. The method according to claim 9 or 12, further comprising administering a compound selected from the group consisting of a growth factor, a cytokine, a co-stimulatory molecule and a mitogenic factor.
18. A method of identifying an APC recruitment or proliferation factor, comprising:
(a) identifying a set of unique DNA sequence tags corresponding to mRNAs expressed in a sample cell that secretes an APC recruitment or proliferation factor;
(b) identifying a set of sequence tags corresponding to mRNA
transcripts expressed in a control cell that does not secrete an APC
recruitment or proliferation factor;
(c) comparing the sequence tags for the sample cell with those of the control cell to identify transcripts that are differentially expressed in the sample cell;
(d) using the sequence tags corresponding to the differentially expressed transcripts identified in part (c) to clone the cDNAs from which the tags were derived and in so doing identify candidate cDNAs that may encode an APC
recruitment or proliferation factor; and (e) expressing the candidate cDNAs identified in (d) to determine which specific cDNAs encode APC recruitment or proliferation factors.
(a) identifying a set of unique DNA sequence tags corresponding to mRNAs expressed in a sample cell that secretes an APC recruitment or proliferation factor;
(b) identifying a set of sequence tags corresponding to mRNA
transcripts expressed in a control cell that does not secrete an APC
recruitment or proliferation factor;
(c) comparing the sequence tags for the sample cell with those of the control cell to identify transcripts that are differentially expressed in the sample cell;
(d) using the sequence tags corresponding to the differentially expressed transcripts identified in part (c) to clone the cDNAs from which the tags were derived and in so doing identify candidate cDNAs that may encode an APC
recruitment or proliferation factor; and (e) expressing the candidate cDNAs identified in (d) to determine which specific cDNAs encode APC recruitment or proliferation factors.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7890998P | 1998-03-20 | 1998-03-20 | |
US60/078,909 | 1998-03-20 | ||
PCT/US1999/006071 WO1999047179A1 (en) | 1998-03-20 | 1999-03-19 | COMPOSITIONS AND METHODS FOR ENHANCED ANTIGEN DELIVERY TO ANTIGEN PRESENTING CELLS $i(IN VIVO) |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2322699A1 true CA2322699A1 (en) | 1999-09-23 |
Family
ID=22146952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002322699A Abandoned CA2322699A1 (en) | 1998-03-20 | 1999-03-19 | Compositions and methods for enhanced antigen delivery to antigen presenting cells in vivo |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1071470A1 (en) |
JP (1) | JP2002506834A (en) |
AU (1) | AU3193999A (en) |
CA (1) | CA2322699A1 (en) |
WO (1) | WO1999047179A1 (en) |
-
1999
- 1999-03-19 JP JP2000536418A patent/JP2002506834A/en not_active Withdrawn
- 1999-03-19 EP EP99913986A patent/EP1071470A1/en not_active Withdrawn
- 1999-03-19 WO PCT/US1999/006071 patent/WO1999047179A1/en not_active Application Discontinuation
- 1999-03-19 AU AU31939/99A patent/AU3193999A/en not_active Abandoned
- 1999-03-19 CA CA002322699A patent/CA2322699A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1999047179A1 (en) | 1999-09-23 |
EP1071470A1 (en) | 2001-01-31 |
AU3193999A (en) | 1999-10-11 |
JP2002506834A (en) | 2002-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1068296B1 (en) | Compositions for eliciting an immune response to a telomerase antigen | |
US6306640B1 (en) | Melanoma antigenic peptides | |
AU758265B2 (en) | Induction of immunity against tumor self-antigens | |
EP1064390A1 (en) | Enhanced anti-tumor immunity | |
CA2403681A1 (en) | Therapeutic anti-cytomegalovirus compounds | |
US20020006412A1 (en) | Preparation and use of particulates composed of adenovirus particles | |
AU759765B2 (en) | Compositions and methods for antigen-specific vaccination | |
AU755706B2 (en) | Methods to provoke anti-cancer immune responses | |
CA2322699A1 (en) | Compositions and methods for enhanced antigen delivery to antigen presenting cells in vivo | |
AU753926B2 (en) | Novel complementing receptor-ligand pairs and adoptive immunotherapy using same | |
AU755156B2 (en) | Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby | |
US7014848B1 (en) | Enhanced anti-tumor immunity | |
JP2004525072A (en) | Anti-melanoma therapeutic compound | |
WO1999046984A1 (en) | Compositions and methods for the frozen storage of dendritic cells | |
CA2411040A1 (en) | Therapeutic anti-melanoma compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |